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Preface  
 
 
This thesis describes my work between January 2006 and March 2010 at the 
Instituto de Medicina Molecular (Lisbon, Portugal) and at the Massachusets 
General Hospital (Boston, USA). My goal was the identification of novel genes 
and pathways involved in antigen presentation. Here I present the main results 
divided in five sections. 
 
In the introduction, I present a brief overview of key immunology concepts 
with special emphasis on dendritic cell biology and antigen presentation.  
 
The second chapter is dedicated to the results of my work, both in 
collaborative projects and within my own project. It is organized in three parts. 
In part 1, I introduce RNA interference and its application in high-throughput 
approaches, along with the publications relating to this type of screens in which 
I participated within this period. In a second section is included an aditional 
collaborative work involving the application of RNA interference techniques in 
the identification of a novel gene with a role in antigen cross-presentation. In 
the last part (subdivided in two sections), I describe the use of a lentiviral shRNA 
library to systematically identify genes with a role in antigen cross-presentation 
in bone marrow derived dendritic cells. 
 
Concluding remarks and future perspectives are presented in the third 
chapter, followed by a materials and methods chapter and an appendix section. 
 
The results presented in this work were reported in various scientific meetings 
and journals or are under preparation for submission: 
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Abstract  
 
 
Effective immune responses against tumor antigens that are not endogenously 
expressed by dendritic cells (DCs) and against virus that do not infect antigen 
presenting cells (APCs) require extracellular antigens to stimulate CD8+ T cells 
via the MHC I pathway through a process known as cross-presentation. 
The molecular mechanisms that direct endocytosed antigens from the 
classical MHC II-restricted presentation pathway to the MHC I pathway are for 
the most part not understood. We have completed a screen for genes with a role 
in this process using a subset of an shRNA lentiviral library enriched for mouse 
kinases and phosphatases. In this screen we measured the proliferation of CD8+ 
T (OT-I) cells in response to the stimulation of bone marrow derived DCs 
(BMDCs) by OVA-expressing S. cerevisiae. After testing over 1000 genes in 
duplicate and two rounds of phenotypic validation, we have chosen ~80 genes 
that reproducibly caused increased (more than 1.5 SDEV) or reduced (less than 
1.2 SDEV) rates of CD8+ T proliferation. 
We also tested these 80 genes in a similar assay but using B3Z as the 
responder cell line. We have found that 15 genes caused a significant change in 
the levels of IL-2 production. Because IL-2 production by this cell line requires 
presentation of the SIINFEKL peptide by MHC I but it is co-stimulator 
independent, it is likely that this group of genes regulates presentation while the 
other group regulates co-stimulator induction. 
We performed qPCR validation of the knockdowns and additional secondary 
screens on this group of 80 genes so that we could identify those that are 
specifically required for cross-presentation. Among these we validated 1 novel 
gene that seems to be predominatly involved in cross-presentation, which is a 
good candidate for follow-up mechanistic studies. Interestingly, it is neither a 
kinase nor a phosphatase. 
Therefore, my results suggest that the overwhelming majority of kinases and 
phosphatases involved in antigen presentation play a role in both canonical and 
antigen cross-presntation pathways. In the hope to find genes that specifically 
regulate antigen cross-presentation, I decided to expand our search to include 
most known genes with a role in vesicle traffic within the cell. In this second 
phase of our screen we measured the proliferation of CD8+ T (OT-I) cells in 
response to the stimulation of BMDCs after incubation with soluble OVA. After 
testing 155 genes, we have chosen 44 genes that reproducibly caused increased 
(more than 1.0 SDEV) or reduced (less than -0.7 SDEV) rates of CD8+ T 
proliferation to be tested in the MHC class II pathway. We found 12 genes that 
caused a significant change in the levels of OT-I proliferation, but had moderate 
or no effect on Class II antigen presentation. We performed qPCR validation of 
the knockdowns on this group of 12 genes and identified 8 novel genes with 
  x 
good correlation profiles. These are excellent candidates for future mechanistic 
studies and the exploration of their in vivo role in antigen cross-presentation in 
different biologically relevant contexts.  
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Resumo  
 
 
Uma resposta imunitária eficaz contra antigénios tumorais, que não são 
endogenamente expressos por células dendríticas, e contra vírus que não 
infectem células apresentadoras de antigénios, requer a estimulação de células 
T CD8+ por parte de antigénios extracelulares via moléculas MHC I, num 
processo denominado de “apresentação cruzada de antigénios”. 
Os mecanismos moleculares que direccionam antigénios endocitados do 
processo clássico de apresentação restringido a moléculas MHC II, para a via de 
classe I são largamente desconhecidos.  
Realizámos um screen com o objectivo de identificar genes envolvidos neste 
processo, usando uma parcela de uma biblioteca lentiviral de shRNA 
enriquecida em cinases e fosfatases de ratinho. Neste screen, foi medida a 
proliferação de células T CD8+ (OT-I) em resposta à estimulação de células 
dendríticas derivadas da medula óssea após incubação com S. cerevisiae 
expressando ovalbumina. Após testar mais de 1000 genes em duplicado e 
realizando duas fases de validação fenotípica, foram escolhidos cerca de 80 
genes que repetidamente causaram um aumento (mais de 1.5 SDEV) ou 
diminuição (menos de -1.2 SDEV) na taxa de proliferação de células T CD8+. 
Os referidos 80 genes foram igualmente testados num ensaio idêntico 
utilizando a linha celular B3Z. Foram identificados 15 genes cuja secreção de 
interleucina-2 (IL-2) foi significativamente diferente dos controlos. Dado que a 
secreção de IL-2 por esta linha celular requer a apresentação do péptido 
SIINFEKL associado à molécula de MHC I, mas esta é independente da 
expressão de moléculas co-estimuladoras, é plausível que este grupo de genes 
possa regular a apresentação, enquanto que os restantes tenham um papel na 
indução de co-estimuladores. 
Realizaram-se validações por qPCR dos níveis de knockdown, bem como 
screens secundários adicionais no grupo de 80 genes para que pudessem ser 
identificados os especificamente envolvidos na apresentação cruzada de 
antigénios. Neste grupo identificámos 1 gene que parece estar 
predominantemente envolvido na apresentação cruzada em antigénios, o qual é 
um bom candidato para estudos mecanísticos posteriores. 
Os resultados descritos sugerem que a maioria das cinases e fosfatases 
envolvidas na apresentação de antigénios desempenham um papel quer na via 
canónica, quer na de apresentação cruzada dos mesmos. Como tal, decidimos 
expandir a nossa pesquisa por forma a incluir todos os genes descritos com um 
papel no tráfego vesicular da célula. Nesta segunda fase, medimos a 
proliferação de células T CD8+ (OT-I) em resposta à estimulação de células 
dendríticas derivadas da medula óssea incubadas com ovalbumina solúvel. 
Após testar 155 genes no contexto da apresentação cruzada de antigénios, 
  xii 
foram escolhidos 44 genes que reprodutivelmente causaram um aumento (mais 
de 1.0 SDEV) ou diminuição (menos de -0.7 SDEV) na taxa de proliferação de 
células T CD8+ para serem testados no contexto de apresentação por moléculas 
MHC II.  
 
Foi observado que 12 genes causam uma alteração específica nos níveis de 
proliferação de células OT-I e com um efeito moderado ou mesmo inexistente 
ao nível da apresentação em classe II. Realizaram-se validações por qPCR dos 
níveis de knockdown destes 12 genes e foram identificados 8 genes com bons 
perfis de correlação. Estes constituem excelentes candidatos para futuros 
estudos mecanísticos e para a investigação do seu papel in vivo na 
apresentação cruzada de antigénios em diferentes contextos biológicos.
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Chapter I - Introduction 
 
 
Innate and Adaptive Immunity/Antigen presentation 
 
 
The human immune system relies on innate and adaptive components to 
achieve highly efficient and specific responses against microbial pathogens. 
Innate immunity is the first line of defense and is evolutionarily ancient and 
conserved, where the central players are phagocytes including macrophages 
and dendritic cells (DCs). Acquired immunity is involved in elimination of 
pathogens in the late phase of infection as well as the generation of 
immunological memory (Akira et al., 2006). The innate immune recognition 
system relies on a limited number of germ line-encoded receptors (Pattern 
Recognition Receptors – PPRs) that evolved to recognize highly conserved 
microbial components, i.e., known as pathogen-associated molecular patterns 
(PAMPs), which are essential for the survival of the microorganisms and 
therefore difficult for the microorganism to alter. Among the best-characterized 
PRRs in mammals are the Toll-like receptors (TLRs) (Beutler, 2004; Janeway and 
Medzhitov, 2002; Takeda et al., 2003). TLRs are either localized at the plasma 
membrane where they recognize microbial products including bacteria cell wall 
components (the canonical example is LPS recognition by TLR4), or within 
endosomal compartments where they are able to sense exposed microbial 
nucleic acids. In addition, other receptors have been identified to recognize 
specific microbial components, namely: nucleotide-binding and 
oligomerization domain (NOD)-like receptors (NLRs) (Fritz et al., 2006; Inohara 
et al., 2005; Martinon and Tschopp, 2007), retinoic acid-inducible gene I (RIG-
I)-like receptors (RLRs) (Yoneyama et al., 2008) and some C-type lectin receptors 
(CLRs) (Geijtenbeek et al., 2004; Robinson et al., 2006; Willment and Brown, 
2008). RLRs and NLRs have a cytoplasmic location, sharing its ligands with 
I. Introduction 
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TLRs, although with quite different molecular basis and outcomes. Table 1 
summarizes the PRRs identified so far, their location and ligand counterparts. 
 
Table 1 - PRRs and cognate microbial ligands. Adapted from (Ishii et al., 2008). 
 
ND - Not determined. FcϒR – Fc receptors for IgG. 
 
 
The identification of these conserved microbial molecular structures enables 
the host to distinguish infectious non-self from non-infectious self and to initiate 
 PAMPs TLRs (transmembrane) 
RLRs  
(cytoplasm) 
NLRs  
(cytoplasm) 
CLRs 
(membrane-
bound) 
Structural 
proteins 
TLR2, TLR4 ND ND ND 
DNA TLR9 DAI? NALP3? FcϒR Virus 
RNA 
TLR3, TLR7, 
TLR8 
RIG-I, MDA5, 
LGP2 
NALP3 FcϒR 
Cell wall 
components 
TLR2/1, TLR2/6, 
TLR4 
ND 
NOD1, NOD2, 
NALP1, NALP3 
Collectins 
Flagellin TLR5 ND IPAF, NAIP5 ND 
Perotoxins ND ND NALP3 ND 
DNA TLR9 ND ASC ND 
Bacteria 
RNA ND ND NALP3 ND 
GPIs TLR2, TLR4 ND ND ND 
Malarial 
hemozoin 
TLR9 ND ND ND 
Proteins (T. cruzi 
Tc52, profilin) 
TLR2, TLR11 ND ND ND 
Protozoan 
DNA TLR9 ND ND ND 
Lipids TLR2 ND ND ND 
Helminths 
RNA TLR3 ND ND ND 
Cell wall 
components 
TLR2, TLR4, 
TLR6 ND ND 
Mannose 
receptor, DC-
SIGN, Dectin 1 
and 2, CARD9 
Fungi 
DNA TLR9 ND ND ND 
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 an immune response. Furthermore, PRR signalling is instrumental for the 
orchestration specific character of the adaptive immune response (fig. 1). 
 
 
Figure 1 – Schematic representation of the integration between the two components 
of the immune response: innate and adaptive immunity. Innate immunity provides the 
first line of defense against microorganisms, through the engagement of PRRs. Upon 
their activation, pathogens will be processed, producing antigens to be presented at the 
surface, namely of dendritic cells, to B and/or T cells. The resulting outcome may lead to 
a suitable immune response, to the microorganism proliferation or the development of 
an autoimmune response. Adapted from (Hoebe et al., 2004). 
 
The internalization of pathogens is an ancient adaptation and is at the center 
of the immune response. In primitive organisms, phagocytosis is primarily used 
for acquisition of nutrients. In higher organisms, it occurs in specialized cells 
(macrophages, neutrophils and dendritic cells) and plays an important role in 
immune defense and homeostasis (fig. 2). 
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Figure 2  - Phagocytosis is involved in distinct cell functions. In unicellular 
organisms, like Dictyostelium, it is essentially involved in nutrition. In higher organisms, 
plays a role not only at the immune system level, but also in the removal of dying cells 
during embryogenesis, as well as in tissue remodelling in adult organisms. From 
(Desjardins et al., 2005). 
 
The sequence of events in phagocytosis can be divided in several steps: (1) 
target recognition; (2) particle internalization; (3) phagosome formation and 
maturation and, in specialized cells, (4) antigen presentation. 
 
Cells bind the pathogens via phagocytic receptors that initiate cytoskeletal 
rearrangements and membrane trafficking required for phagocytosis. After 
pathogen internalization, the phagosome matures to become a phagolysosome 
where the pathogen is killed by a wide variety of microbicidal mechanisms, 
including reactive oxygen and nitrogen intermediates and toxic peptides. The 
dead microbes are then digested, mainly through the action of hydrolases, and 
microbial peptides are loaded into the major histocompatibility complex (MHC) 
molecules through an intricate route of membrane trafficking. Once the 
peptides are bound to the MHC molecule, these complexes are translocated to 
the cell surface, where the peptide/MHC complex binds to its cognate T cell 
receptor (TCR), with the engagement of co-stimulatory molecules, namely 
 I. Introduction 
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 CD80, CD86 and CD40. This process, called antigen presentation, results in 
specific T cell activation and is at the interface between the innate and adaptive 
immune systems. Concomitantly, the antigen-presenting cells (APCs) will 
secrete inflammatory mediators, including cytokines that further instruct other 
immune cells, namely, the T cells. These fall into distinct functional classes, 
which include TH1 cells, whose main function is to activate macrophages to kill 
the intravesicular pathogens they harbor; TH2 cells which activate B cells for 
antibody production; TH17 cells that mediate inflammatory responses and tissue 
repair and regulatory T cells (Treg) that suppress the immune response. 
 Though several cell types can act as antigen-presenting cells, there are three 
that are classified as professional APCs, for their ability to express MHC class II 
molecules and to engage co-stimulatory signalling: dendritic cells, macrophages 
and B-cells. 
Figure 3 shows a schematic illustration of the key steps in antigen 
presentation. 
 
Figure 3 - Productive T cell activation requires three APC (in this example, a dendritic 
cell) signals. Signal 1 is the recognition of the MHC molecules-associated peptides by 
the cognate TCR. Signal 2 relates to the co-stimulatory signals expressed by dendritic 
cells, mainly CD80 and CD86, upon pathogen recognition through Pattern Recognition 
Receptors (PRRs). Signal 3 refers to the secretion of various factors, namely interleukin-
12 (IL-12), that promote the development of either TH1 or TH2 cells. The outcome of 
signal 3 is influenced by the engagement of a certain PRR of a specific microorganism. 
Adapted from (Kapsenberg, 2003). 
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The immune system employs different pathways to process intracellular and 
extracellular antigens. Classically, two antigen presentation pathways are 
distinguished: on one hand, peptides derived from proteins of endogenous 
origin within APCs (namely, those resulting from viral infections, from the 
presence of intracellular bacteria or even from alterations within the cell) are 
loaded into MHC class I molecules for presentation to CD8+ T cells; on the other 
hand, MHC class II molecules present peptides with an exogenous origin to 
CD4+ T cells (fig. 4). 
In the case of endogenous antigens, the proteins are degraded into short 
peptides by a cytosolic proteolytic system – the proteasome. The resulting 
peptides are then shuffled to the ER through a transporter associated with 
antigen presentation (TAP). Concomitantly, the assembly of the MHC class I 
molecule complex takes place, with the recruitment of several molecular 
chaperones, namely, calnexin, β2-microglobulin, tapasin, calreticulin and 
ERp57, that also regulate the acquisition of the antigenic peptide. Upon stable 
peptide binding, the class I molecule dissociates from its chaperone 
counterparts, exits the ER and proceeds to the cell surface (Ackerman and 
Cresswell, 2004; Kloetzel, 2004; Rock et al., 2004). 
 
In the MHC class II antigen presentation pathway, extracellular antigens are 
internalized (by phagocytosis and/or endocytosis) and upon endosome 
formation, this compartment experiences several changes, followed by its fusion 
with lysosomes, forming endolysosomes, where the interaction with the MHC 
molecules occurs (Vyas et al., 2008). The class II molecule complexes are 
transported from the endoplasmic reticulum (ER) through the various endocytic 
compartments, during which the invariant chain that blocks the binding of 
endogenous antigen is continuously degraded. The remaining fragment – CLIP – 
(class II-associated invariant chain peptide) is then substituted by the antigenic 
peptide, and the peptide-class II complex moves to the cell surface, where it is 
presented (Jensen, 2007). 
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 However, there are exceptions to these canonical routes, that tentatively 
explain how it is possible to elicit a cytotoxic T lymphocyte (CTL) response 
against tumour cells or viruses that do not infect APCs. This phenomenon was 
first described by (Bevan, 1976) who coined the term “cross-presentation”. 
 
 
Figure 4 - Antigen presentation pathways. Peptides derived from proteins of endogenous 
origin are loaded into MHC class I molecules for presentation to CD8+ T cells. MHC class II 
molecules present peptides of exogenous origin to CD4+ T cells. Under some circumstances, 
exogenous antigens may diverge from the canonical MHC class II pathway and MHC class I 
molecules may acquire peptide cargo from this origin. Adapted from (Villadangos and 
Schnorrer, 2007). 
 
In cross-presentation, extracellular antigens, which are normally presented in 
association with MHC class II molecules, are instead presented by MHC class I 
molecules (Groothuis and Neefjes, 2005). In vitro, it has been shown that 
several cell types are able to cross-present, namely, dendritic cells (Albert et al., 
1998a; Albert et al., 1998b), macrophages (Harding and Song, 1994; Norbury et 
al., 1995), B cells (Ke and Kapp, 1996), neutrophils (Tvinnereim et al., 2004) 
and more recently, even mast cells (Stelekati et al., 2009). Nevertheless, it is 
now consensual that the cross-presenting cell type of excellence is the dendritic 
cell (Carbone and Bevan, 1990; Jung et al., 2002; Sigal and Rock, 2000; Smith 
et al., 2003). 
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Dendritic cells are comprised of several subsets and present a ubiquitous 
distribution. The distinction between different DC subsets is an issue of debate, 
with the possibility of using several classifications. When considering murine 
subsets, one possible categorization is to distinguish between DC subsets in the 
steady state (and within these, the ones migratory or resident to lymphoid 
organs) and in inflammatory conditions (monocyte derived) (William Heath, 
personal communication). The resident subsets can be classified according to 
surface markers (CD4+, CD8+ and double negative (DN)), while the migratory 
subtypes can be discriminated in Langerhans cells, dermal cells and more 
recently, also in CD103+ DCs (Pulendran et al., 2008). In addition to 
“conventional” DCs, another category is considered: the plasmacytoid DCs 
(pDCs). The later circulate in the blood and lymphoid tissues and upon 
activation, secrete type I interferons (IFNs)(Villadangos and Schnorrer, 2007). 
Plasmacytoid DCs have constituted a proficuous research area in the DC field in 
past years, particularly with several implications in viral immunity (Colonna et 
al., 2004; Reinicke et al., 2009; Villadangos and Young, 2008), though many 
aspects of their cell biology and antigen presenting capabilities are still issue of 
debate. More recently, (Heath and Carbone, 2009) have suggested the 
distinction between four major dendritic cell subgroups with the assignment of 
generalized functions: the pDCs promoting innate immunity; CD11b+ DCs 
contribute to CD4+ T cell responses; CD11b- DCs priming cytotoxic T cells and 
monocyte-derived DCs acting in the stimulation of effector or memory T-cells 
recruited to the inflammation site.  
Table 2 lists the major mouse dendritic cell subsets, their location, surface 
markers and functional features in homeostatic conditions. 
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 Table 2 - Mouse dendritic-cell subsets. Adapted from (Pulendran et al., 2008; 
Villadangos and Schnorrer, 2007; Villadangos and Young, 2008). 
Lymphoid-organ-resident DC 
subsets 
Migratory DC subsets Plasmacytoid 
Monocyte 
derived Features 
CD4+ CD8+ DN Interstitial Langerhans  
Location       
Spleen Yes Yes Yes No No Yes Sites of 
inflammation 
Subcutaneous 
lymph nodes 
Yes Yes Yes Yes Yes Yes  
Visceral lymph 
nodes 
Yes Yes Yes Yes No Yes  
Thymus Yes Yes Yes No No Yes  
Surface markers   
CD11c +++ +++ +++ +++ +++ + +++ 
CD4 + ⎯ ⎯ ⎯ ⎯ ⎯ ⎯ 
CD8 ⎯ ++ ⎯ ⎯ -/+ -/+ ⎯ 
CD205 ⎯ ++ -/+ + +++ ⎯ -/+ 
CD11b ++ ⎯ ++ ++ ++ ⎯ ++ 
Langerin ⎯ + ⎯ ⎯ +++ ⎯ ⎯ 
CD24 + ++ + ND ND ⎯ ND 
SIRPα + ⎯ + + + ⎯ ND 
B220 ⎯ ⎯ ⎯ ⎯ ⎯ ++  
Ly6C ⎯ ⎯ ⎯ ⎯ ⎯ ++  
Functional features in the steady state  
Maturity Immature Immature Immature Mature Mature Immature N/A 
Co-stimulatory + + + ++ ++ + N/A 
Antigen 
processing and 
presentation 
+++ +++ +++ +/- +/- ++ N/A 
MHC class II ++ ++ ++ +++ +++ + N/A 
DN – Double negative. ND – not determined. SIRPα - signal-regulatory protein α. 
 
Dendritic cells acquire antigens from infected cells in the periphery, and then 
migrate to the lymph nodes where they display antigenic peptides in association 
with MHC class I molecules. MHC class I peptide complexes are recognized by 
antigen-specific CD8+ cytotoxic T lymphocytes, which become activated and 
expand in response to antigen recognition (Heath et al., 2004). Cross-
presentation of cellular antigens is involved in many different responses, 
including those against tumors, viruses, graft tissues and even autoimmunity 
(Heath and Carbone, 2001). 
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Different DC subtypes show different cross-presentation ability, favourable to 
the CD8+ sub-type, although all subsets present similar capability in the uptake 
of both soluble and particulate antigens (den Haan et al., 2000; Pooley et al., 
2001; Schnorrer et al., 2006).  Table 3 summarizes examples of cross-presented 
antigens and the corresponding DC subtype. In addition, it has been shown that 
both CD8+ and CD8- DC subsets are able to cross-prime antigen in the form of 
immune complexes (den Haan and Bevan, 2002). 
 
Table 3 - In vivo cross-priming and corresponding presenting DCs. Adapted from 
(Belz et al., 2002b; Lin et al., 2008). 
 
DC subset Antigen Immunity against Reference 
CD8+ 
OVA-coated 
splenocytes − 
(den Haan et al., 
2000) 
CD8+ Apoptotic cells − 
(Iyoda et al., 2002; 
Schulz and Reis e 
Sousa, 2002) 
CD8+ Soluble OVA − (Pooley et al., 2001) 
CD8+, CD4+, DN Soluble OVA+LPS − (Pooley et al., 2001) 
CD8+ Virus 
Cutaneous HSV-1 
Cutaneous and 
systemic HSV-1, 
influenza, vaccinia 
(Allan et al., 2003; 
Allan et al., 2006; 
Belz et al., 2002b; 
Smith et al., 2003) 
CD8- Virus 
Porcine parvovirus-
like particles 
LCMV virus-like 
particles 
(Moron et al., 2002; 
Ruedl et al., 2002) 
CD8+ and CD8- Virus 
Respiratory HSV-1 
and influenza 
(Belz et al., 2004) 
CD8- 
Shigella toxin subunit 
B-OVA 
Tumour (Vingert et al., 2006) 
CD8+ Intracellular bacteria 
Listeria 
monocytogenes 
(Belz et al., 2005) 
HSV, herpes simplex virus; LCMV, lymphocytic choriomeningitis virus; LPS, lipopolysaccharide. 
 
As mentioned above, cross-presentation is also implicated in the recognition of 
self-antigen, causing deletion of reactive CTLs, a process also termed as cross-
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 tolerance (Davey et al., 2002; Kurts et al., 1997). Table 4 presents some 
examples of different DC subsets involved in reported cross-tolerance studies. 
Particularly, the pioneering work by the Steinman group using ovalbumin 
(OVA)-loaded apoptotic cells “deleting” the recognizing CD8+ T cells 
counterparts should be pointed out (Liu et al., 2002). 
 
Table 4 - In vivo cross-tolerance and corresponding presenting DCs. Adapted from (Belz 
et al., 2002b; Lin et al., 2008). 
DC subset Antigen Site Reference 
CD8+ OVA-loaded 
apoptotic cells 
Spleen (Liu et al., 2002) 
CD8+ OVA-expressed in 
islet β cells 
Pancreatic LN (Belz et al., 2002a) 
DEC-205+ Anti-DEC-205-OVA Spleen (Bonifaz et al., 2002) 
CD8- Intestinal soluble 
OVA 
Mesenteric LN (Chung et al., 2005) 
CD8- OVA expressed in 
keratinocytes 
Superficial LN 
(Waithman et al., 
2007) 
LN, lymph node. 
 
Although receptor-independent mechanisms such as phagocytosis and 
pinocytosis are of great relevance in antigen cross-presentation, accumulating 
evidence has implicated several receptors in this process, namely Fc receptors 
(den Haan and Bevan, 2002), mannose receptor (Burgdorf et al., 2007) and C-
type lectins (Bonifaz et al., 2004). 
The signaling pathways and molecular mechanisms at the center of cross-
presentation are largely unknown. Two main pathways for cross-presentation 
have been described: (1) the cytosolic pathway (fig. 5), in which the exogenous 
antigen exits phagosomes to the cytosol for degradation by the proteasome 
(Arnold et al., 1995; Fonteneau et al., 2003; Kovacsovics-Bankowski and Rock, 
1995; Li et al., 2001; Norbury et al., 1995; Reis e Sousa and Germain, 1995) 
and (2) the vacuolar pathway (fig. 6), where the antigenic peptides are 
generated within phagosomes by endoproteases (Shen et al., 2004). 
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(1) Cytosolic pathway 
 
In this model, internalized antigen is translocated to the cytosol of APCs 
(Delamarre et al., 2003; Rodriguez et al., 1999), where it is degraded by the 
proteasome (Cresswell et al., 2005). The resulting antigens are then loaded on to 
the endoplasmatic reticulum (ER) and ultimately presented at the cell surface in 
association with MHC class I molecules.  As such, this model of antigen cross-
presentation shares some similarities with the classical MHC class I pathway, as 
it also makes use of the proteasome complex and the transporters associated 
with antigen processing (Brossart and Bevan, 1997; Kovacsovics-Bankowski and 
Rock, 1995). Furthermore, there is evidence that cross-presentation is sensitive 
to a drug, Brefeldin A, that acts upon protein export from the ER, which supports 
this model (Brossart and Bevan, 1997; Kovacsovics-Bankowski and Rock, 1995; 
Nuchtern et al., 1989). In addition, other studies show that another drug, 
chloroquine, an inhibitor of lysosomal acidification, enhances cross-
presentation (Accapezzato et al., 2005; Bertholet et al., 2006). 
Another relevant aspect to have in consideration in this pathway of cross-
presentation is how the antigen reaches the cytosol; there is accumulating 
literature that points to the existence of a channel that selectively allows the 
antigen “exit” from the phagosome to the cytosol (Rodriguez et al., 1999; Tsai et 
al., 2002). The exact nature of this channel is still matter of debate (Lilley and 
Ploegh, 2004; Ye et al., 2004), although the ER-associated degradation (ERAD) 
pathway component molecules Sec61 (Imai et al., 2005) and Derlin1 (Lilley and 
Ploegh, 2004; Ye et al., 2004) have been suggested as candidates. 
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Figure 5 - Possible routes for cytosolic pathway of antigen cross-presentation. Adapted 
from (Lin et al., 2008). 
 
 
 
 
 
(2) Vacuolar pathway 
 
In opposition to the cytosolic pathway, another cross-presentation pathway 
that is proteasome and TAP independent has been described (Rock and Shen, 
2005; Schirmbeck and Reimann, 2002). In this pathway, termed vacuolar 
pathway (fig. 6), exogenous antigens are processed within the phagosomes by 
endoproteases (namely, cathepsin S) for subsequent loading into the MHC-I 
molecules and consequent migration and presentation at the cell surface 
(Norbury et al., 1995; Pfeifer et al., 1993; Shen et al., 2004). 
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Figure 6 - Vacuolar pathway of antigen cross-presentation. Adapted from (Lin et al., 
2008). 
 
In summary, we can highlight three important aspects that contribute to the 
relevance of antigen cross-presentation: (1) a major surveillance route for 
pathogens (namely, virus) that do not infect APCs; (2) a tumor recognition 
mechanism, signaling for its destruction by cytotoxic T cells and (3) a system 
that enables the establishment of tolerance to self-antigens. However, it should 
be added that some studies have failed to demonstrate cross-presentation under 
some conditions (Kundig et al., 1995; Ochsenbein et al., 2001; Ohashi et al., 
1991). Many of these studies have used the lymphocytic choriomeningitis virus 
as an antigen source; it has been shown that a mutant of this virus that retains 
the antigen longer in the ER, “rescues” the cross-presentation phenotype 
(Freigang et al., 2007), making it possible that some virus may by-pass cross-
presentation as a survival strategy.  
 
As previously referred, the signaling pathways and molecular mechanisms 
underlying cross-presentation remain poorly understood. We therefore decided 
to take an unbiased approach with the purpose of identifying novel genes with a 
role in antigen cross-presentation. For that, we made use of an RNA interference 
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 (RNAi) approach targeting functional families of genes. The underlying basis 
of the mechanism, its advantages and caveats in high-throughput application 
and the employment of RNAi techniques in an immunologic context will be 
discussed in the following chapter. 
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Chapter II - Results 
 
Part 1 
 
RNAi  
 
RNAi was first described in plants in the early 90’s, though at the time not 
designated as such (Ecker and Davis, 1986; Napoli et al., 1990). Only later, 
through the seminal work of Andrew Fire and Craig Mello in C. elegans, for 
which they have received the 2006 Nobel Prize in Physiology or Medicine, was 
it possible to begin to understand this process (Fire et al., 1998). 
Indeed, little more than a decade ago, few might have envisioned that this 
mechanism would constitute one of the most widely used approaches to 
address problems in all areas of biology, as the RNAi core machinery is 
conserved in almost all eukaryotic systems. 
RNAi is an endogenous cellular process by which messenger RNAs are 
targeted for degradation by double-stranded RNA (dsRNA) of identical 
sequence, leading to gene silencing (Fire et al., 1998) (fig. 7). Long dsRNA 
molecules are cleaved into small interfering RNAs (siRNA), 21 to 25 nucleotides 
long, by an enzyme termed Dicer and its associated proteins, namely the trans-
activation-responsive RNA-binding protein (TRBP) (Bernstein et al., 2001). The 
siRNA molecules are then loaded into the RNA-induced silencing complex 
(RISC), with cleavage of the RNA sense strand of the siRNA molecules by 
Argonaute 2 (AGO2) (Rand et al., 2004). This activated RISC-siRNA complex 
targets, binds and degrades complementary mRNA molecules (Ameres et al., 
2007). If the complementarity between the siRNA and the targeted mRNA is 
incomplete in the “seed” region (nucleotides 2 to 8 from the 5’ end of the guide 
strand), with base-pairing usually occurring in the 3’UTR, there are several 
possible results: inhibition of translational initiation or elongation, de-
II. Results 
 
22 
adenylation or the transport to cytoplasmic “P-bodies” for degradation 
(Valencia-Sanchez et al., 2006). 
Moreover, in addition to the above described post-transcriptional gene 
silencing (PTGS), another RNAi mechanism occurs in the nucleus: RNAi 
mediated transcriptional gene silencing (TGS) (Zaratiegui et al., 2007). In this 
later mechanism, siRNAs may target complementary gene promoter sequences 
(Han et al., 2007; Morris et al., 2004; Ting et al., 2005), induce epigenetic 
modifications such as histone and DNA methylation (Janowski et al., 2005; 
Weinberg et al., 2006), as well as changes in the local chromatin structure 
(Zaratiegui et al., 2007).  
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Figure 7 - Schematic representation of the RNAi mechanism. Long dsRNA (or in alternative 
shRNAs or siRNAs) is introduced into the cytoplasm, where it is cleaved into siRNA by the 
enzyme Dicer. The siRNA molecules are then incorporated into RISC, with the cleavage of the 
RNA sense strand of the siRNA molecule by AGO2. The activated RISC-siRNA complex targets, 
binds and degrades complementary mRNA molecules. The activated RISC–siRNA complex can 
then be recycled for the destruction of identical mRNA targets. Adapted from (Whitehead et al., 
2009). 
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Several endogenous small RNAs have been identified in various organisms, 
namely C. elegans, Drosophila, mouse and humans (which are believed to 
originate from transposons, viruses and repetitive sequences), and are reviewed 
in table 5 (Castanotto and Rossi, 2009). 
 
 
Table 5 - Cellular small RNAs involved in gene silencing. Adapted from (Castanotto and 
Rossi, 2009). 
Class Size (nt) Functions Mechanism Origin Organism 
siRNAs 21-25 
Regulating gene 
expression, 
providing antiviral 
response, 
restricting 
transposons 
RNA 
degradation, 
transposon 
restriction 
Intergenic 
regions, 
exons, introns 
C. elegans, D. 
melanogaster, S. 
pombe, A. 
thaliana, O. 
sativa 
endo-siRNAs 21-25 
Restricting 
transposons, 
regulating mRNAs 
and 
heterochromatin 
RNA 
degradation 
Transposable 
elements, 
pseudogenes 
D. melanogaster, 
mammals 
miRNAs 21-25 
Regulating gene 
expression at the 
post-
transcriptional 
level 
Blocking 
translation, 
RNA 
degradation 
Intergenic 
regions, 
introns 
C. elegans, D. 
melanogaster, S. 
pombe, A. 
thaliana, O. 
sativa, mammals 
piRNAs 24-311 
Regulating 
germline 
development and 
integrity, silencing 
selfish DNA 
Unknown 
Defective 
transposon 
sequences 
and other 
repeats 
C. elegans, D. 
melanogaster, D. 
rerio, mammals 
ra-siRNAs 23-28 
Remodeling 
chromatin, 
transcriptional 
gene silencing 
Unknown 
Repeated 
sequence 
elements 
(subset of 
piRNAs) 
C. elegans, D. 
melanogaster, S. 
pombe, T. 
brucei, D. rerio, 
A. thaliana 
ta-siRNAs 21-22 
Trans-acting 
cleavage of 
endogenous 
mRNAs 
RNA 
degradation 
Non-coding 
endogenous 
transcripts 
D. melanogaster, 
S. pombe, A. 
thaliana, O. 
sativa 
natRNAs 21-22 
Regulating gene 
expression at the 
post-
transcriptional 
level 
RNA 
degradation 
Convergent 
partly 
overlapping 
transcripts 
A. thaliana 
                                                
1 C. elegans piRNAs are 21 nucleotides. 
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scnRNAs 26-30 
Regulating 
chromatin 
structure 
DNA 
elimination 
Meiotic 
micronuclei 
T. thermophila, 
P. tetraurelia 
tncRNAs 22 Unknown Unknown 
Non-coding 
regions 
C. elegans 
siRNAs, short interfering RNAs; endo-siRNAs, endogenous siRNAs; miRNAs, microRNAs; natRNAs, natural antisense 
transcript siRNAs; piRNAs, PIWI-interacting RNAs, ra-siRNAs, repeat-associated siRNAs; scnRNAs, scan RNAS; ta-
siRNAs, trans-acting siRNAs; tncRNAs, tiny non-coding RNAs. 
 
Initially, RNAi was used to knock down selected genes of interest. However, 
this technology was quickly adjusted to a genome scale, allowing genome-wide 
loss-of-function screening. It has also become an option for the discovery and 
development of new drugs (Kramer and Cohen, 2004). From classical model 
organisms such as C. elegans and Drosophila, to mosquitoes and mammalian 
systems, the examples of its application are numerous (Ashrafi et al., 2003; 
Boutros et al., 2004; Kuttenkeuler and Boutros, 2004; Parry et al., 2007; 
Samuelson et al., 2007; Zender et al., 2008). More recently, the application of 
RNAi strategies against various human diseases has experienced an 
enhancement (Kim and Rossi, 2007). Some examples of diseases that have been 
or are under study for RNAi applications include age-related macular 
degeneration (AMD)(Check, 2005; McFarland et al., 2004), respiratory syncytial 
virus (RSV) infection (Bitko et al., 2005) and several HIV studies in cultured 
human cells (Coburn and Cullen, 2002; Jacque et al., 2002; Lee et al., 2002; 
Novina et al., 2002). In addition, there are several RNAi based preclinical 
approaches for several cancers as reviewed by (Pai et al., 2006) and 
neurodegenerative disorders (Raoul et al., 2005). Table 6 summarizes on-going 
RNAi based clinical trials. 
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Table 6 - Examples of on-going clinical trials using an RNAi-based therapeutic. Adapted 
from (Castanotto and Rossi, 2009). 
siRNA Company Disease Stage 
Wet age-related 
macular 
degeneration 
Phase III 
Bevasiranib Acuity Pharmaceuticals 
Diabetic 
macular 
oedema  
Phase II 
Sirna-027 Merck-Sirna 
Therapeutics 
Wet age-related 
macular 
degeneration 
Phase II 
RTP801i-14 
Quark 
Pharmaceuticals 
and Silence 
Therapeutics 
Wet age-related 
macular 
degeneration 
Phase I/IIA 
ALN-RSV01 Alnylam 
Pharmaceuticals 
Respiratory 
syncytial virus 
infection 
Phase II 
NUC B1000 Nucleonics Hepatitis B Phase I 
Anti-tat/rev 
shRNA 
City of Hope 
National 
Medical Center 
and Benitec 
AIDS 
Pilot 
feasibility 
study 
CALAA-01 Calando Pharmaceuticals Solid tumours Phase I 
TD101 
TransDerm and 
the 
International 
Pachyonychia 
Congenita 
Consortium 
Pachyonychia 
congenita 
Phase I 
 
 
However, the effective delivery of the RNAi molecules remains a challenge 
to its use in a clinical setting, as many tissues can only be reached through 
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intravenous systemic administration of delivery agents. Furthermore, several 
obstacles have to be overcome, like the possible uptake by phagocytes, 
aggregation with serum proteins or the enzymatic degradation by endogenous 
nucleases (Alexis et al., 2008). Hence, the more advanced clinical trials 
presented in table 6 relate to local and directed applications of this therapy. 
Nevertheless, intensive work is being pursued for the development of different 
vehicles for siRNA and shRNA delivery, namely synthetic polymers, 
natural/biodegradable polymers and lipids (Rao et al., 2009b; Whitehead et al., 
2009). 
As a summary, figure 8 represents a chronological description of the 
milestones in RNAi discovery and knowledge.  
 
 
 
 
1 (Napoli et al., 1990); 2 (Lee et al., 1993); 3 (Guo and Kemphues, 1995); 4 (Fire et al., 1998); 5 (Hammond et al., 2000); 6  (Zamore et al., 2000); 7, 9 (Elbashir et 
al., 2001b); 8 (Elbashir et al., 2001a); 10 (Brummelkamp et al., 2002; Paddison et al., 2002); 11 (Song et al., 2003); 12 (Rubinson et al., 2003); 13 (Berns et al., 
2004; Paddison et al., 2004); 14 (Zaehres et al., 2005); 15 (Li et al., 2006). 
 
Figure 8 - Brief chronological description of major discoveries in the RNA interference field. 
Adapted from (Shrivastava and Srivastava, 2008). 
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RNAi Screens 
 
The approaches used to set up RNAi screens have many similarities to the 
ones applied so far in more classical screenings. However, some differences 
arise, namely at the level of phenotype evaluation, which may implicate new 
levels of automation and analysis, and also depending on the extent of 
screening in question (for example, at a genome screening level or “just” parts 
of it). 
RNAi screens present two advantageous aspects over classical genetic 
screens: the sequences of the target genes are known a priori and lethal 
mutations are easily identified (Boutros and Ahringer, 2008). Concomitantly, 
RNAi approaches may present variability and unspecific gene knockdown. 
Several studies (reviewed by (Echeverri and Perrimon, 2006)) have documented 
various off-target effects (OTEs), particularly in mammalian systems. The effects 
can be found in basically all types of RNAi systems used so far, which include 
synthetic small interfering RNAs (siRNAs) and vector based short hairpin RNAs 
(shRNAs). As these authors refer, one of the primary sources of off-target effects 
relies in the high tolerance for mismatches between the RNAi molecule and the 
complementary target mRNA sequence, also termed as “sequence-dependent 
off-target effects”.  However, recently has been suggested that shRNA 
approaches produce fewer off-target effects than siRNAs, as shRNA is 
transcribed in the nucleus and as such, enrolls in endogenous processing; 
moreover, siRNA delivery to the cytoplasm may experience degradation, 
leading to off-target silencing (Rao et al., 2009a; Rao et al., 2009b). 
Nevertheless, several available software tools♦ can be used in the design of 
siRNA sequences that aim in minimizing this problem (Moffat et al., 2006; 
Naito et al., 2005; Qiu et al., 2005). Another aspect to consider is that for the 
case of siRNAs, these may also function as miRNAs (Doench et al., 2003; 
Scacheri et al., 2004), and as such, unintentionally silence transcripts at a 
translational level by partial complementarity.  
                                                
♦ http://dscheck.rnai.jp/,  http://rnai.cs.unm.edu/rnai/off-target/sirna_freq/, 
http://rnai.cs.unm.edu/rnai/off-target/genes-targeted/, 
http://www.broad.mit.edu/genome_bio/trc/publicSearchForHairpinsForm.php  
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One final caveat relating to sequence-dependent OTEs is the triggering of 
interferon response (Marques and Williams, 2005). As (Shan, 2009) points out, a 
particular issue in these unwanted immune responses, relates to the engagement 
of TLRs, as some siRNAs have a higher propensity for doing so, and as such, are 
known as isRNA (immunostimulatory RNA) (Hornung et al., 2005; Judge et al., 
2005). In addition, it has been reported that siRNAs with 3’ blunt ends (these are 
recognized by another PRR – RIG-I helicase -) and GU enriched sequences are 
highly immunoreactive, aspects that should be taken in consideration in siRNA 
design (Marques et al., 2006; Schlee et al., 2006). 
To minimize the risks of sequence-dependent off-target effects in RNAi 
approaches, (Echeverri et al., 2006) have published consensual guidelines: 1) 
rescue experiments; 2) redundancy of several RNAi reagents, i.e., several 
different RNAi constructs providing the same phenotype; 3) control other off-
target effects, which are not sequence correlated by using “scrambled” RNAi 
sequences. Although these “scrambled” controls are designed to not target any 
known sequence, it is impossible to rule out that these may trigger some 
uncontrolled effects on their own. Alternatively, they suggest the usage of the 
mean readout from several unspecific RNAi constructs to set-up a control 
baseline. 
Another category of RNAi off-target effects are the “sequence independent 
off-target effects”, which include poorly characterized events, such as ones 
triggered by chemical or structural features of the silencing and/or delivery 
reagents themselves. These also trigger interferon responses, and include 
toxicity aspects of delivery reagents, along with the risk of the usage of high 
concentrations of silencing reagents that might compete with endogenous 
miRNAs (Ohrt et al., 2006). 
In sum, it has to be taken into consideration that “the high rates of apparent 
false positives that are often picked up in the first stage of large-scale screens, 
and the failure of repeated efforts to confirm some single siRNAs results with 
multiple other siRNAs, strongly supports the idea that such effects are real and 
relatively common” (Echeverri and Perrimon, 2006). 
Finally, though RNAi has been used for targeting mRNA, recent reports claim 
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the application of RNAi to non-coding RNAs transcribed by Pol II – HOTAIR - 
(Rinn et al., 2007); nevertheless, its efficacy in targeting other non-coding RNAs 
remains to be established. 
 
 
Design of RNAi screens 
 
 
Defining the aim and the question to answer  
 
The first challenge when performing a screen is to define a clear question to 
answer, as this will influence all the following design and set-up steps. As 
(Boutros and Ahringer, 2008) state, two situations should be considered: 1) 
trying to identify some unknown mechanisms of a process that is, nevertheless, 
well understood and for that, take a direct approach; or 2) aiming to study a 
more unclear field (which was the case of object of this work), and as such, 
endeavor the screening of a broad range of genes that may be implicated in it. 
 
 
Screen format 
  
When deciding to perform a large-scale cell-based RNAi screen, an 
important issue is the type of screen format to choose. It may be an arrayed 
screen, which targets each gene individually, or a pooled screen, targeting 
many genes at the same time, with a selection approach. The two options 
present advantages and limitations, which have to be taken into consideration 
along with the biological question and set-up at hand. 
An arrayed screen allows choosing to screen a subset of target genes or the 
entire genome, if available, in an individual fashion. This is the most 
straightforward manner to apply RNAi screening and the approach that 
encompasses a larger range of possible phenotypes to be screened. 
Nevertheless, as (Echeverri and Perrimon, 2006) mention, the effort in 
optimization that this type of screens poses in terms of sensitiveness and 
robustness of the assays, in order to obtain reproducibility, along with its cost,  
is sometimes overwhelming. 
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Pooled screens allow the silencing of an entire collection of genes to a 
unique population of cells, relying in the possibility of selecting the cells 
presenting the loss-of-function phenotype. This obviously offers the possibility of 
performing a screen in a much faster, simpler and inexpensive way, but it 
should be emphasized that the phenotypes of interest have to confer a 
selectable characteristic to the cells. Figure 9 summarizes the possible decisions 
to take into account when performing RNAi screening. 
  
 
 
 
Figure 9 - Decisions to consider in RNAi screening. Adapted from (Echeverri and 
Perrimon, 2006; Sharma and Rao, 2009). 
 
 
Set-up of screen assay/Pilot screen  
 
“A robust and specific assay is the most important element of a successful 
RNAi screen” (Boutros and Ahringer, 2008). This statement summarizes and 
stresses the critical importance of this step. It is probably one of the most time- 
and labour-consuming stages of RNAi screening, as it requires a vast effort in 
testing several parameters and conditions.  
The first concern is the specificity of the assay towards the mechanism of 
study. However, too many times the simplicity of the essay is inversely 
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proportional to its specificity (Boutros and Ahringer, 2008). As such, one has “to 
find a compromise between specificity and practicality”. 
Additionally, positive and negative controls should be selected and tested in 
the assay set-up. These controls may provide invaluable information for defining 
later “hit genes”.  However, it should be added that the selection of adequate 
control genes might not be possible when the studied processes are poorly 
described.  
Usually, the cut-off at which a gene is selected as a hit is determined by 
analyzing the data from the whole screen, besides looking at the control genes 
data. Some “assumed” cut-offs such as 2-3 standard deviations from the mean, 
should be looked as guidelines, in order to obtain a robust and reliable study.  
After setting-up the experimental assay and choosing the control genes, a 
small “pilot screen”, in which the control genes, along with a few number of 
other genes are tested, should be conducted. This will provide valuable 
information, namely concerning practical aspects of conduction of these large-
scale experiments. For example, the necessary incubator space, the time 
required for each step and output acquisition (microscopy time, FACS 
acquisition), amount of reagents, among others.  
In summary, the final quality of the screen will rely very much in the 
minimization of the sources of variability that affect reproducibility: 
experimental design, technical implementation, data processing and the 
inherent biological variability. 
 
 
The screen 
  
The primary screens are many times conducted in duplicate in order to 
increase the confidence of the selected hits and to avoid the false negatives that 
arise in large-scale screening (Boutros and Ahringer, 2008). So, after this first 
stage of screening, the expected results should be a hit list of genes that 
produced a reproducible phenotype in both screening duplicates. 
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Secondary/Validation screen 
 
In the secondary screen, all the genes that were selected as hits in the 
primary screen should be re-tested in the same previous conditions and in a 
duplicate fashion. This is all too important if it was not decided to conduct the 
primary screen in duplicate, due to some constraint. The secondary screen will 
indicate the robustness of the hits and provide some hints about its biological 
relevance. In addition, other screens, probing some other aspects of the role of 
the selected genes, can be conducted as validation screens, which will provide 
further information about their specificity and possible putative role in the 
studied mechanism. 
The final step is to compare in parallel the phenotypic read-out and the level 
of gene knockdown, at the mRNA level usually by determining RNA level by 
qRT-PCR or at the protein level by western blotting, confirming the correlation 
between both. 
 
 
Result analysis 
 
The analysis of the screens results depends on the type of assay and screening 
procedure. In the case of a large screen, a huge range of gene scores will be 
produced and only the ones presenting a strong phenotype will be chosen. In 
addition, it should also be considered for the follow up assays that the chosen 
hit genes may be a result of one of the following situations: either the gene has a 
strong effect and was targeted by partial knockdown; or the gene expression 
was strongly suppressed although it had a weaker effect; or in fact the gene may 
be a “master regulator” and it was almost fully knocked-down. Particularly in 
the case of large-scale screens, it is of crucial importance also to include 
statistical analysis in order to select relevant gene hits. This analysis includes a 
normalization method and a hit identification step. (Birmingham et al., 2009) 
have recently reviewed several of the normalization and statistical analysis 
methods for hit identification, pointing out advantages and limitations for each.  
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RNAi screening in C. elegans 
 
C. elegans is a classical model organism, which was the first to experience  a 
systematic RNAi use.  
There are several methods by which RNAi can be achieved in C. elegans, all 
of which remarkable by their simplicity, namely injection or soaking of dsRNA 
or by feeding the worms bacterial strains that express dsRNAs (Tabara et al., 
1998; Tabara et al., 1999; Tavernarakis et al., 2000; Timmons et al., 2001; 
Timmons and Fire, 1998). Currently there are two “RNAi feeding” libraries, 
which together target approximately 87% of the worm genome (Fraser et al., 
2000; Kamath et al., 2003; Rual et al., 2004). Several whole-genome high-
throughput screens have been conducted, identifying genes in major biological 
pathways such as fat regulatory, aging and miRNA function (Ashrafi et al., 2003; 
Parry et al., 2007; Samuelson et al., 2007). 
So far, no cell lines are available from this organism, and as such, only 
whole-animal screens are possible (Boutros and Ahringer, 2008). 
 
 
RNAi screening in Drosophila 
 
Contrary to what was previously referred for C. elegans, there are several 
Drosophila cell lines that enable cell-based RNAi screens for this organism 
(some examples are the work by (Boutros et al., 2004; Kuttenkeuler and Boutros, 
2004); in particular, S2 cell cultures are usually used in this type of studies, 
which have enabled the identification of novel genes implicated in cytokinesis, 
cell cycle regulation signaling pathways and virus replication (Bjorklund et al., 
2006; Bonaldi et al., 2008; DasGupta and Gonsalves, 2008; Hao et al., 2008; 
Mattila et al., 2008). It is possible to perform this type of assays by adding 
synthesized dsRNAs to cell culture medium, as described by (Clemens et al., 
2000).  
Also, similarly to C. elegans, it is possible to perform RNAi screens in vivo in 
Drosophila, although these are technically more challenging. Usually, adult flies 
and embryos may be injected with dsRNA targeting the desired genes 
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(Kennerdell and Carthew, 2000; Koizumi et al., 2007; Pilot et al., 2006). More 
recently, libraries of transgenic flies expressing RNAi hairpins have been 
produced at a genome scale as well (Boutros and Ahringer, 2008; Dietzl et al., 
2007). 
 
 
RNAi screening in mammalian cells 
  
In mammalian systems, RNAi screens are by and large cell based (Echeverri 
and Perrimon, 2006). As dsRNAs elicit an interferon response, contrary to the 
organisms referred above, in the case of human cells (for example), it is 
necessary to use siRNAs (synthetic RNAs) of 21-23 nucleotides to achieve 
interference evading unwanted effects (Elbashir et al., 2001a). Currently, there 
are available siRNA, plasmid-based shRNA and virus-based shRNA libraries for 
high-throughput screening with human and mouse cell cultures (Boutros and 
Ahringer, 2008; Chang et al., 2006; Fewell and Schmitt, 2006; Ganesan et al., 
2008; Root et al., 2006). In particular, with the currently available vector-based 
short hairpin libraries (shRNA), like the one used in the present work, it is 
possible the knockdown of genes in cell types difficult to transfect, like primary 
cells. Indeed, primary cells have shown to present serious difficulties to high-
throughput RNAi screening, as many are refractory to common lipid and 
peptide methods of transfection (Ovcharenko et al., 2005). The usage of virally 
delivered shRNA vectors has made this approach possible. Although early viral 
libraries were not routinely used for high-throughput RNAi screening because of 
the difficulties in producing a high titre of virus on a large scale, (Moffat et al., 
2006) have described an shRNA lentiviral library developed at the Broad 
Institute of MIT and Harvard that allowed to individually screen 5,000 shRNAs 
targeting about 1,000 human genes in a high-content imaging screen for mitotic 
progression. More recently, it was reported the application of RNAi screening in 
vivo at the whole organism level in mice, using a shRNA pool to identify tumor 
suppressors in liver cancer (Zender et al., 2008). Although the costs, lack of 
human resources and of compatible biological assays may still pose a difficulty 
in large RNAi applications, there are many examples of its success (table 7). 
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Table 7 - Examples of large RNAi screens in human cells. Adapted from (Paddison, 
2008). 
Screen Cell type RNAi trigger 
Genes 
targeted 
Reference 
Apoptosis HeLa siRNA 510 (Aza-Blanc et al., 
2003) 
Cell survival HeLa siRNA 872 (MacKeigan et al., 
2005) 
26s proteasome 
function 
293 shRNA 4873 
(Paddison et al., 
2004) 
Cell division HeLa esiRNA 5305 (Kittler et al., 
2004) 
Transformation HMEC shRNA ~9000 
(Westbrook et al., 
2005) 
Cisplatin 
sensitization 
HeLa siRNA ~20000 
(Bartz et al., 
2006) 
Mitotic 
progression 
HT29 shRNA ~1000 
(Moffat et al., 
2006) 
Trans-acting 
factors required 
for CD45RO 
expression 
JSL1 shRNA 
 
~440 
(Oberdoerffer et 
al., 2008) 
β-catenin 
activity and 
colon cancer 
cell proliferation 
DLD-1 shRNA ~1000 
(Firestein et al., 
2008) 
esiRNA, endoribonuclease-prepared siRNAs; HMEC, human mammary epithelial cells. 
 
Another aspect worth mention is that the knockdown efficiencies of the 
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individual RNAi constructs vary, and along with the possible off-target effects, 
lead to the usage of several siRNAs per gene. 
 
 
The RNAi Consortium (TRC) library 
 
It has been observed that virus-mediated integration of an RNAi expression 
cassette is the most efficient method for long-term gene suppression and use in a 
broad range of cell types (Root et al., 2006). After integration, the cassette 
produces a short dsRNA molecule, usually in the form of a hairpin structure, 
short hairpin RNA (shRNA), which is processed into active small interfering 
RNA (siRNA). 
The consortium selected pLKO.1 as the library vector, to maximize viral titers 
and resistance to plasmid recombination. Indeed, (Moffat et al., 2006) show that 
even after 10 rounds of sequential regrowth of several library clones, no 
evidence of recombination was observed. The pLKO.1 lentiviral vector is a 
derivative of pRRLSIN.cPPT.PGK/GFP/WPRE (Stewart et al., 2003), and is a 
third-generation self-inactivating lentiviral vector (Dull et al., 1998; Zufferey et 
al., 1998). A human U6 promoter was introduced to drive the expression of 
shRNAs, and the vector contains a PGK promoter driving expression of the 
puromycin resistance gene to allow selection of transduced cells (fig. 10). Like 
other third generation lentiviral vectors, viruses are generated using a three 
plasmid packaging system (i.e. the different necessary components of the viral 
genome are introduced in separate plasmid vectors, along with a viral envelope) 
to minimize the potential for recombination to create replication competent 
viruses. A schematic representation of a lentiviral vector production for stable 
shRNA expression is shown in figure 11.                
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Figure 10 - Vector map for the pLKO.1 lentiviral vector. From (Moffat et al., 2006). 
 
 
 
 
 
 
 
 
Figure 11 - Representation of lentivirus expressing shRNAs production using three 
plasmid packaging system. Packaging host cells (such as 293T cells) are transfected with 
a mixture of plasmids consisting of: 1) an shRNA expression cassette; 2) a packaging 
cassette and 3) a heterologous (commonly VSV-G) viral envelope expression cassette. 
The generated lentivirus is then used to transduce the target cell type of option for 
shRNA expression. Only the vector containing the shRNA expression cassette is 
integrated into the genome of the target cells, and as such, shRNA is continually 
expressed but infectious virus is not produced. Adapted from (Manjunath et al., 2009). 
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The hairpin sequences contain stems of 21 nucleotides that exactly match the 
target transcript, and are selected using an algorithm designed to increase 
likelihood of good target gene knockdown, to avoid off-target effects and to 
disperse the 21-mer sequences across the target transcript (Moffat et al., 2006). 
Each gene is targeted by an average of five distinct shRNA constructs and at 
least four shRNAs are available for over 96% of targeted genes. Also, for the 
majority of the genes, the library contains shRNAs that target both coding 
sequence (CDS) and the 3’ untranslated region (UTR) of their transcripts. The 
first stage of the TRC library produced 160.000 shRNA constructs targeting 
15.000 mouse and 15.000 human genes; the second phase (initiated in 2007 
and on-going) aims at producing at least two highly efficient targeting constructs 
for every human and mouse genes. 
 
 
 
Future and challenges 
 
From what has been presented, it becomes obvious that RNAi screens will 
contribute to new knowledge in a vast spectrum of processes and mechanisms. 
It has become a common experimental option in many labs, with the easiness of 
access to this type of technology, though the generation of results from high-
throughput RNAi screens in several experimental contexts is still at the 
beginning. It is clear also that RNAi in vertebrates poses many more challenges 
and difficulties of implementation than in invertebrates, including those related 
to off-target effects. As such, the design and implementation of these high-
throughput experiments should be carefully planned. 
This technology has undergone a high rate of development and 
improvement, which is expected to continue in the future.  As different authors 
highlight (Boutros and Ahringer, 2008; Echeverri et al., 2006) the number of 
available softwares and applications for the analysis and implementation of 
these high-throughput assays has been increasing exponentially, but there are 
still many caveats to be overcome, and in particular, RNAi screen data storage 
has became a pressing matter, along with the definition of standard vocabulary 
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and guidelines for these assays. These authors even suggest the adoption of the 
minimum information about a microarray experiment (MIAME) standards in 
RNAi experiments (MARIE), which would provide a common platform for all 
users of RNAi datasets. 
However, RNAi applications have become a highly promising tool in both 
basic and applied research, enabling the study of many subjects in a way that 
was not possible before. As (Paddison, 2008; Shan, 2009) anticipate, RNAi 
technology will aim to validate drug activities and disease models both in vitro 
and in vivo, along with the identification of new therapeutical targets, besides 
being a therapeutical possibility by itself, encompassing a huge enthusiasm in 
the biomedical community in what can be achieved by it.  
In conclusion, RNAi screening is very much summarized by the following 
statement by (Boutros and Ahringer, 2008): “the end of the screen is the 
beginning of the experiment”. 
 
 
 
Immunity and RNAi 
 
Like other areas of biological research, the immunology field is profuse in 
questions that may be addressed by RNAi methodologies. In recent years, there 
have been accumulating reports using RNAi to address immunity related 
questions. In particular, the Drosophila field has provided several contributions 
on innate immunity associated subjects. Examples are the works reported by the 
Ezekowitz group on phagocytosis (Ramet et al., 2002), the Lemaitre group and 
co-authors on identification of Imd pathway (cognate mammalian TNF-receptor 
pathway) components (Kleino et al., 2005) and regulators of the Toll-pathway 
(Kambris et al., 2006) and the Perrimon group on host factors necessary for 
mycobacterial infection (Philips et al., 2005). Also, (Stroschein-Stevenson et al., 
2006)  have identified proteins required for C. albicans phagocytosis using RNAi 
approaches and more recently, (Cronin et al., 2009) have reported the discovery 
of pathways involved in intestinal pathogenic bacterial infection,  to name a few 
examples. 
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 With the better understanding of the RNAi, and the development of new 
RNAi delivery strategies (which are discussed further on this work), the success 
of these approaches in invertebrates was extended to mammalian systems. 
Though still at its infancy (specially in what concerns the usage of primary cells 
in this type of approaches), studies have been conducted to dissect virus-host 
cell interactions (Krishnan et al., 2008; Zhou et al., 2008) and in the 
identification of a regulator of CD45 alternative splicing (which marks the 
transition from naïve to activated T cells) (Oberdoerffer et al., 2008). 
 
The next sections are composed of submitted or published work that report 
important findings in diverse aspects of the immune response using RNAi as a 
central technology driving discovery and where I had an important role. These 
are examples that were important to develop my expertise to perform screens 
using RNAi and that were critical for me to begin to approach the more 
complex core subject of my thesis using the same technology: antigen cross-
presentation. 
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Rab27a and Rab27b control different steps of the exosome 
secretion pathway 
 
Exosomes are secreted membrane vesicles that share structural and biochemical 
characteristics with intraluminal vesicles of multivesicular endosomes (MVEs). 
Exosomes could be involved in intercellular communication and in the 
pathogenesis of infectious and degenerative diseases. The molecular 
mechanisms of exosome biogenesis and secretion are, however, poorly 
understood. Using an RNA interference (RNAi) screen, we identified five Rab 
GTPases that promote exosome secretion in HeLa cells. Among these, Rab27a 
and Rab27b were found to function in MVE docking at the plasma membrane. 
The size of MVEs was strongly increased by Rab27a silencing, whereas MVEs 
were redistributed towards the perinuclear region upon Rab27b silencing. 
Thus, the two Rab27 isoforms have different roles in the exosomal pathway. In 
addition, silencing two known Rab27 effectors, Slp4 (also known as SYTL4, 
synaptotagmin-like 4) and Slac2b (also known as EXPH5, exophilin 5), inhibited 
exosome secretion and phenocopied silencing of Rab27a and Rab27b, 
respectively. Our results therefore strengthen the link between MVEs and 
exosomes, and introduce ways of manipulating exosome secretion in vivo. 
 
 
My contribution for this work included the design of the lentiviral screened 
collection (by doing extensive bioinformatics analysis on genes related to 
vesicle traffic), assembly of the collection and lentiviral production. I have also 
participated in the screen design and gave practical and theoretical input at 
different stages of the screen. 
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Novel HIV-1 Knockdown Targets Identified by an Enriched 
Kinases/Phosphatases shRNA Library Using a Long-Term Iterative 
Screen in Jurkat T-Cells 
 
 
HIV-1 is a complex retrovirus that uses host machinery to promote its 
replication. Understanding cellular proteins involved in the multistep process of 
HIV-1 infection may result in the discovery of more adapted and effective 
therapeutic targets. 
Kinases and phosphatases are a druggable class of proteins critically involved in 
regulation of signal pathways of eukaryotic cells. Here, we focused on the 
discovery of kinases and phosphatases that are essential for HIV-1 replication 
but dispensable for cell viability. We performed an iterative screen in Jurkat T-
cells with a short-hairpin-RNA (shRNA) library highly enriched for human 
kinases and phosphatases. We identified 14 new proteins essential for HIV-1 
replication that do not affect cell viability. These proteins are described to be 
involved in MAPK, JNK and ERK pathways, vesicular traffic and DNA repair. 
Moreover, we show that the proteins under study are important in an early step 
of HIV-1 infection before viral integration, whereas some of them affect viral 
transcription/translation. This study brings new insights for the complex 
interplay of HIV-1/host cell and opens new possibilities for antiviral strategies. 
 
My contribution for this work included the assembly of the collection and 
lentiviral production. I also gave practical and theoretical input at different 
stages of the screen. 
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Synaptogamins, regulators of calcium-dependent vesicle fusion, are 
required for cell migration 
 
 
Chemokines and other chemoattractants direct leukocyte migration and thus are 
essential for the development and delivery of immune and inflammatory 
responses. 
Chemoattractants induce their biological effects by binding and activating G 
protein coupled chemoattractant receptors (GPCRs), which results in a transient 
increase in intracellular free calcium, and the formation of a leading edge 
lamellipodium and a trailing uropod. However, much remains to be learned 
about the identity and coordination of the many cellular and molecular 
processes needed to carry out the complex process of chemottractant-induced 
directed cell migration. To probe the cellular mechanisms underlying this 
process more deeply, we performed an RNAi screen and identified members of 
the synaptotagmin (SYT) family of membrane proteins, which mediate calcium-
dependent vesicle fusion, as critical mediators of cell migration. SYT7 and the 
related gene SYTL5 were positive regulators while SYT2 was a negative 
regulator of chemotaxis, consistent with their opposing roles in regulating 
lysosomal exocytosis. Rab27a and Rab3a, small GTPases that regulate lysosome 
transport and interact with the identified synaptotagmin proteins, were identified 
as additional positive regulators of chemotaxis. Confirming the RNAi studies, 
leukocytes from SYT7-deficient mice had a decrease in chemoattractant 
induced migration and calcium-dependent lysosomal fusion ex vivo. In vivo, 
SYT7-deficient mice exhibited a leukocyte recruitment defect in a urate crystal-
induced murine model of gout. In a chemokine gradient, SYT7-deficient 
lymphocytes accumulated lysosomes in their uropods and showed prolonged 
attachment to the culture substrate at the uropod. Together, these results identify 
a molecular pathway required for chemotaxis that links chemoattractant-
induced calcium flux to vesicle exocytosis and uropod release. 
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My contribution for this work included assistance with the initial screening and 
in microscopy acquisition images. 
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The MHC class Ib protein ULBP1 is a non-redundant determinant 
of leukemia/lymphoma susceptibility to γδ  T-cell cytotoxicity 
 
On the path to successful immunotherapy of hematopoietic tumors, γδ T-cells offer 
great promise due to their HLA-unrestricted targeting of a wide variety of 
leukemias/lymphomas. However, the molecular mechanisms underlying lymphoma 
recognition by γδ T-cells remain unclear. Here we show that the expression levels 
of UL16-binding protein 1 (ULBP1) determine lymphoma susceptibility to γδ T-cell-
mediated cytolysis. 
Consistent with this, blockade of NKG2D, the receptor for ULBP1 expressed on all 
Vγ9+ T-cells, significantly inhibits lymphoma cell killing. Specific loss-of-function 
studies demonstrate that the role of ULBP1 is non-redundant, highlighting a thus far 
unique physiological relevance for tumor recognition by γδ T-cells. Importantly, we 
observed a very wide spectrum of ULBP1 expression levels in primary biopsies 
obtained from lymphoma and leukemia patients. We suggest this will impact on the 
responsiveness to γδ T-cell-based immunotherapy, and therefore propose ULBP1 to 
be used as a leukemia/lymphoma biomarker in upcoming clinical trials. 
 
 
My contribution for this work included the shRNA lentiviral production used for 
targeting the studied genes and practical and theoretical guidance during the 
knockdown of selected genes. 
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Part 2 
 
The small GTPase Rac2 controls phagosomal alkalinization and 
antigen crosspresentation selectively in CD8+  dendritic cells 
 
 
In this second section is included an additional collaborative work involving 
the application of RNA interference techniques in the identification of a novel 
gene with a role in antigen cross-presentation. The Amigorena group has 
provided valuable contributions to this field in the past years, namely in the 
study of phagosomal pH regulation during antigen processing for dendritic cell 
cross-presentation (Jancic et al., 2007; Savina et al., 2006). In the work 
presented bellow, it is shown that Rac2 plays a critical role in antigen cross-
presentation in CD8+ DCs by determining the subcellular localization of NOX2 
to phagosomes. My contribution to this work was the development and 
application of the BMDC lentiviral infection protocol (there were no previous 
reports of infection and successful gene knockdown in Dendritic Cells), the 
evaluation of its efficiency for both Rac1 and Rac2 genes and the selection of 
the most effective constructs that were used throughout the reported work. 
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Part 3 
 
Genetic Dissection of Antigen Cross-Presentation in Bone Marrow-
Derived Dendritic Cells 
 
Results and Discussion 
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To date, few genes have been shown to have a role in antigen cross-
presentation. As a result, our understanding of the process remains rudimentary, 
as are the possibilities to use it in the fight against viral infection and cancer. In 
order to take an unbiased approach in the study of antigen cross-presentation, 
we chose to make use of a subset of the mouse lentiviral collection developed 
by the TRC in order to identify novel genes involved in this process.  We started 
by developing an in vitro assay to measure antigen cross-presentation.  
C57BL/6 mice were used as donors for BMDCs. Because cellular proteins 
have been identified as the predominant form of cross-presented antigens in 
vivo (Heath et al., 2004) and according to availability, we chose OVA 
expressing yeast (Saccharomyces cerevisiae) as an antigen source. OT-I mice 
were used as a source of naïve CD8+ T-cells (Hogquist et al., 1994), harboring a 
transgenic T cell receptor that specifically recognizes the OVA residues 257-264 
(SIINFEKL) in the context of H2Kb response. The assay can be summarized in the 
following steps, which are schematically represented in fig. 12: day 0 - isolation 
of bone marrow cells and seeding in 96-well plates in the presence of GM-CSF; 
day 2 - lentiviral infection; day 4 - antibiotic (puromycin) selection of infected 
cells; day 6 - cell number determination, addition of antigen, inflammatory 
cytokine production assessment and T-cell isolation and addition; day 9 - 
addition of tritiated thymidine; day 10 - cell proliferation readings. 
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Figure 12 – Schematic representation of experimental protocol. 
 
 
In a first approach, we conducted preliminary experiments to define several 
parameters for the high-throughput screening, including the determination of 
the number of BMDCs to use, the most adequate proportion of antigen 
challenge (yeast number) and the necessary amount of virus to obtain an 
effective infection. At this point, the lentivirus used was a control construction 
that targets the GFP protein. 
We first addressed the influence of the BMDCs number in terms of the T-cell 
proliferative response, as measured by the incorporation of tritiated thymidine. 
We tested three different cell numbers, which were challenged with a 1:5 
BMDC: yeast ratio and infected with 20 µl of shGFP virus (fig. 13). 
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Figure 13 – Pilot experiment conducted to optimize number of presenting BMDCs. 
BMDCs were challenged with a 1:5 BMDC: yeast ratio. T-cell proliferation is measured 
by tritiated thymidine incorporation (CPM). Sc_OVA – S. cerevisiae expressing OVA; 
Sc_WT - S. cerevisiae wild type. 
 
 
As depicted in fig. 13, 50000 BMDCs was the number of cells that provided 
the best T-cell proliferation. 
We then tested if a smaller volume of virus would produce a similar 
outcome, using the previously tested BMDC numbers. It is also critical to use a 
small as possible amount of virus to minimize the possibility of off-target effects 
and the differentiation of dendritic cells. The yeast: cell ratio was the same as 
previously mentioned. 
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Figure 14 – Pilot experiment conducted to test different lentiviral volumes used to 
infect BMDCs. BMDCs were challenged with a 1:5 BMDC: yeast ratio. T-cell 
proliferation is measured by tritiated thymidine incorporation (CPM). Sc_OVA – S. 
cerevisiae expressing OVA; Sc_WT - S. cerevisiae wild type. 
 
 
From fig. 14 it is possible to conclude that decreasing the viral volume to 
10µl causes no significant differences in the observed T-cell response.  
Finally, two additional cell to yeast ratios were tested: 1:1 and 1:10. From the 
results represented in fig. 15, it was possible to establish that higher cell: yeast 
ratios lead to increased T-cell proliferation. 
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Figure 15 – Summary of pilot experiment conducted to optimize screen parameters. 
Cell number, cell: yeast ratio, as well as lentiviral volume for infection was tested. T-cell 
proliferation is measured by tritiated thymidine incorporation (CPM). Sc_OVA – S. 
cerevisiae expressing OVA; Sc_WT - S. cerevisiae wild type. 
 
 
As a summary, from the results obtained with these pilot experiments, we 
were able to determine 50000 BMDCs and a 1:10 cell: yeast ratio, as the ideal 
antigen presentation set-up, with 10 µl of virus to be sufficient to obtain a 
successful infection rate. These were the key conditions used in the high-
throughput assays. 
 
1. Kinase/phosphatase subset 
 
The definition of constrictions points within signalling pathways has been a 
successful approach when analyzing biological complexity. These constriction 
points often materialize in kinases and phosphatases. As such, the first set of 
genes to be screened was a collection enriched for kinases and phosphatases  
(the complete gene list is included in the supplementary data, table S1). This 
screen summed-up to approximately 1000 tested genes, in duplicate, producing 
more than 10000 individual records. Reproducibility was observed, both for 
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BMDC number after lentiviral infection and puromycin selection (fig. 16), as 
well as for T-cell proliferation across duplicate plates (fig. 17).  
 
 
 
Figure 16 – Reproducible BMDC number across duplicate plates in primary screen. 
 
 
 
Figure 17 – Reproducible T-cell proliferation across duplicate plates in primary 
screen. 
 
 
All the obtained data, both for cell number (figs. S1 and S2) and T-cell 
proliferation (figs. S3 and S4), was imported and integrated in a FileMaker Pro 
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database. Taking advantage of this software integration, scripts were created to 
automatically calculate the number of viable cells in each individual well, along 
with the transformation of the T-cell proliferation for each individual hairpin 
tested into a normalized value: the Z-score.  The Z-score relates to the deviation 
of the mean T-cell proliferation for the plate where it was located, as it reflects 
the experimental set-up experienced for each individual plate (primary cells 
used at that date, viral titer, infection efficiency and other reagents 
effectiveness). As (Birmingham et al., 2009) emphasize, this method uses the 
tested samples for normalization. 
 
 
Z  score = individual well T cell proliferation - plate µ  T cell proliferationplate σ  T cell proliferation  
 
 
 
 
Additionally, it was considered that all records with less than 20000 viable 
cells after antibiotic selection should be excluded from further analysis. As it 
was observed from the preliminary experiments, this is a cell number dependent 
assay, and bellow this threshold, the T-cell proliferation levels would not 
correlate with cross-presentation.  
After sorting all individual records and analyzing them in a graphical 
representation (fig. 18), it was possible to choose the criteria to select candidate 
genes for the follow up validation experiments. This implied that at least one 
construct (reproducible in the duplicate plates) presented a Z-score higher than 
1.5 or lower than -1.2 (fig. 18). From the first set of experiments, approximately 
170 genes (17% of the initial screened genes) were selected for validation in 
follow-up assays according to the above-described criteria. Also, these 170 
genes were tested using the murine MHC class I- B3Z T-cell hybridoma, which 
recognizes the OVA peptide, SIINFEKL, associated with H-2Kb and produces IL-
2 upon this recognition (Karttunen and Shastri, 1991); this cell line is also co-
stimulatory independent (it does not engage the co-stimulatory molecules 
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CD80/CD86 in antigen recognition), and as such, results obtained for any gene 
with this output, may provide insight in this aspect. 
 
 
 
 
 
Figure 18 - The criteria used to select candidate genes for following validation 
experiments, implied that at least one construct (reproducible in the duplicate plates) 
presented a deviation of the mean proliferation for the plate where it was located (Z-
score), higher than 1.5 or lower than -1.2 as depicted in the graph after sorting each 
individual record. 
 
 
 
The genes selected from the primary screen were again tested in a similar 
experimental set-up. After conducting this secondary stage of validation, again 
in duplicate and setting a -1.0 <Z-score <1.2 cut-off as selection criteria (fig. 
19), 81 genes that reproduced the observed phenotype in the primary screen 
were chosen for a tertiary phase of validation.  
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Figure 19 - Secondary screen in which 177 genes were re-tested following previously 
defined experimental conditions. Candidate genes for subsequent validation experiments 
were selected by presenting at least one construct (reproducible in the duplicate plates) 
with a Z-score higher than 1.2 or lower than -1.0. 
 
 
 
 
Figure 20 – IL-2 secretion by B3Z cells (results are represented as a Z-score relating to 
the deviation of each individual hairpin to the mean of the plate where located) 
stimulated by dendritic cells infected with the selected lentivirus targeting hit genes, 
challenged with 1:10 yeast-OVA. 
 
 
From the analysis of the obtained data for IL-2 secretion by B3Z cells (fig. 20) 
and considering the shRNA hairpins that produced top Z-score values (fig. 21), 
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it was possible to identify 15 matching genes (when compared to OT-I T-cell 
proliferation phenotype) whose knockdown produced differential IL-2 secretion.  
 
 
 
 
Figure 21 – Z-score distribution relating to IL-2 secretion by B3Z cells stimulated by 
dendritic cells infected with selected lentivirus targeting hit genes. • - Outlier; ∗ - 
Extreme. 
 
 
A synopsis of the different screening stages is represented in figure 22. 
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Figure 22 - Schematic representation of the followed screening stages. 
 
 
1.2 Characterization of gene hits 
 
 
The tertiary stage of validation comprises assessing different aspects of the 
antigen presentation process for the selected genes. This included evaluating the 
expression of co-stimulatory molecules (CD86), major histocompatibility 
complex molecule expression (H-2Kb), antigen processing and inflammatory 
cytokine (IL-12, IL-6 and TNF-α) production by DCs knocked down for the 
genes of interest.  Also, similar assays as the ones described using OT-I mice 
were performed using OT-II mice for MHC-II context studies, along with the 
evaluation of IFN-γ secretion both in the cross-presentation and class II set-up.  
 
 
 
 
1.2.1 CD86 expression 
 
For the selected genes, DCs were isolated, infected with the lentivirus and 
selected as previously described. At day 6, the cells were challenged with LPS 
(1µg/ml) for 24h, after which they were stained for CD86-FITC and CD11c-PE 
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and analyzed by flow cytometry. A Z-score was determined (as previously 
described for the T-cell proliferation screening) for the CD11c+ /CD86+ 
population of each individual tested hairpin (fig. 23). 
From the data distribution  (fig. 24), it was possible to establish that only the 
shRNA hairpin targeting Dmpk that had produced an OT-I T-cell proliferation 
phenotype also lead to a differential expression of the CD86 co-stimulatory 
molecule.   
 
 
 
 
Figure 23 – CD86 expression (represented as a Z-score, relating to the deviation of 
each individual expression to the mean) in dendritic cells infected with the selected 
lentivirus targeting hit genes, challenged with LPS (1µg/ml). 
 
 II. Results 
129 
 
 
Figure 24 – Z-score distribution relating to CD86 expression in dendritic cells 
infected with selected lentivirus targeting hit genes. • - Outlier 
 
 
1.2.2 Antigen processing 
 
In order to assess if the selected genes may have a role in the processing of 
antigen for presentation by dendritic cells, we made use of a commercially 
available fluorescence substrate: DQ™ ovalbumin. As previously referred, DQ™ 
ovalbumin is an ovalbumin substrate that exhibits bright green fluorescence 
upon proteolytic degradation. 
BMDCs were isolated, infected with the lentivirus coding for the shRNA 
hairpins that provided a T-cell proliferation phenotype and selected as 
previously described. At day 6, the number of viable cells was measured 
through Alamar Blue™ staining and concomitantly, DQ™ ovalbumin was added 
(0.25µg/ml) for 4h, after which fluorescence emission was measured. A Z-score 
was determined as the deviation of the emitted fluorescence per cell for each 
individual tested hairpin to the mean of the plate where it was located (fig. 25). 
From the distribution of the data (fig. 26), it was possible to determine that 
from the shRNA hairpins that lead to higher DQ™ ovalbumin emitted 
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fluorescence, only the ones targeting Gcs1 and Vdac3 genes had also produced 
an OT-I T-cell proliferation phenotype. 
 
 
 
 
Figure 25 – Fluorescence emission/cell of DQ™ ovalbumin (0.25µg/ml), represented 
as a Z-score, relating to the deviation of each individual hairpin to the mean, processed 
in dendritic cells infected with selected lentivirus, after 4h incubation. 
 
 
 
Figure 26 – Z-score distribution relating to the fluorescence emission/cell of DQ™ 
ovalbumin in dendritic cells infected with selected lentivirus targeting hit genes. • - 
Outlier; ∗ - Extreme. 
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1.2.3 H-2Kb expression 
 
BMDCs were isolated, infected with the lentivirus coding for the shRNA 
hairpins that provided a T-cell proliferation phenotype and selected as 
previously described. At day 6, the cells were challenged with LPS (1µg/ml) for 
24h, after which were stained for H-2Kb-PE and CD11c-FITC and analyzed by 
flow cytometry. A Z-score was determined as the deviation of the CD11c+ / H-
2Kb+ cell population for each individual tested hairpin to the mean of the plate 
where it was located (fig. 27). 
From the distribution of the data (fig. 28), we concluded that none of the 
tested genes presented a significant differential expression of the H-2Kb 
molecule.   
  
 
 
 
Figure 27 – H-2Kb expression (represented as a Z-score, relating to the deviation of 
each individual expression to the mean) in dendritic cells infected with the selected 
lentivirus targeting hit genes, challenged with LPS (1µg/ml). 
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Figure 28 – Z-score distribution relating to H-2Kb expression in dendritic cells 
infected with selected lentivirus targeting hit genes. 
 
 
 
1.2.4 Inflammatory cytokine production 
 
BMDCs were isolated, infected with lentivirus targeting hit genes and 
selected as previously described. At day 6, the number of viable cells was 
determined through Alamar Blue™ staining and LPS (1µg/ml) was added for 8h. 
Cell supernatants were collected to assess the production of inflammatory 
cytokines (TNF, IL-6 and IL-12) by ELISA. A Z-score was determined as the 
deviation of cytokine secretion per cell for each individual tested hairpin to the 
mean of the plate where it was located for the three tested cytokines (fig. 29, fig. 
30 and fig. 31). 
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Figure 29 – TNF-α secretion by dendritic cells infected with selected lentivirus after 
LPS (1µg/ml) challenge. Results are represented as a Z-score, relating to the deviation of 
each individual hairpin to the mean of the plate where located. 
 
 
 
Figure 30 – IL-12 secretion by dendritic cells infected with selected lentivirus after 
LPS (1µg/ml) challenge. Results are represented as a Z-score, relating to the deviation of 
each individual hairpin to the mean of the plate where located. 
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Figure 31 – IL-6 secretion by dendritic cells infected with selected lentivirus after LPS 
(1µg/ml) challenge. Results are represented as a Z-score, relating to the deviation of each 
individual hairpin to the mean of the plate where located. 
 
 
In what concerns TNF secretion, we conclude from the data distribution  (fig. 
32) that from the genes that produced an OT-I T-cell proliferation phenotype, 
correlating shRNA hairpins targeting Dmpk, Pin1 and Ptpn7 also generated 
higher cytokine secretion. 
 
 
 
 
Figure 32 – Z-score distribution relating to TNF secretion/cell in dendritic cells 
infected with selected lentivirus targeting hit genes. • - Outlier. 
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In the case of IL-12 secretion, 9 top Z-score targeted genes presented a 
differential IL-12 secretion, which had also produced an OT-I T-cell 
proliferation phenotype (fig. 33).  From these, five were putative negative 
regulators (Dmpk, Dnajc7, Erbb3, Gucy1b2 and Mapk7) and four putative 
positive regulators (Acvr2a, Dnaja2, Doc2b and Pdpk1). 
 
 
 
Figure 33 – Z-score distribution relating to IL-12 secretion/cell in dendritic cells 
infected with selected lentivirus targeting hit genes. • - Outlier; ∗ - Extreme. 
 
 
 
Considering IL-6 secretion, the hairpins knocking down Dmpk and Mapk7, 
which produced an OT-I T-cell proliferation phenotype, were among the ones 
presenting a higher secretion of the referred cytokine (fig. 34).   
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Figure 34 – Z-score distribution relating to IL-6 secretion/cell in dendritic cells 
infected with selected lentivirus targeting hit genes. • - Outlier; ∗ - Extreme. 
 
 
1.2.5 IFN-γ  production 
 
As a measure of T-cell effector function, IFN-γ production by OT-I and OT-II 
cells was evaluated for the shRNA hairpins of the selected genes that provided a 
T-cell proliferation phenotype (fig. 35 and fig. 36, respectively). BMDCs 
isolation, infection and selection, was carried out as previously described. At 
day 6, the number of viable cells was determined by Alamar Blue™ staining and 
soluble OVA (0.1µg/ml) was added. Approximately 6h after, T-cells were 
isolated from OT-I and OT-II mice and added to the BMDCs. IFN-γ production 
was assessed 72h after by ELISA. 
 
 II. Results 
137 
 
 
Figure 35 – OT-I T-cell IFN-γ secretion, primed by dendritic cells infected with 
selected lentivirus, after soluble OVA (0.1µg/ml) challenge. Results are represented as a 
Z-score, relating to the deviation of each individual hairpin to the mean of the plate 
where located. 
 
 
 
Figure 36 – OT-II T-cell IFN-γ secretion, primed by dendritic cells infected with 
selected lentivirus, after soluble OVA (0.1µg/ml) challenge. Results are represented as a 
Z-score, relating to the deviation of each individual hairpin to the mean of the plate 
where located. 
 
Among the top hits (although only three matched an outlier criteria) for 
impacting in IFN-γ production, there were 13 genes correlating with OT-I T-cell 
proliferation phenotype (four putative positive and nine putative negative 
regulators (fig. 37)).  For OT-II IFN-γ production, even if none of the tested 
shRNAs matched an extreme or outlier criteria, among the top hits were eight 
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genes (five putative positive and three putative negative regulators) with a 
phenotype matching that of OT-I T-cell proliferation (fig. 38).  
 
 
 
Figure 37 – Z-score distribution relating to IFN-γ secretion by OT-I T-cells activated 
by dendritic cells infected with selected lentivirus targeting hit genes. • - Outlier. 
 
 
 
 
Figure 38 – Z-score distribution relating to IFN-γ secretion by OT-II T-cells activated 
by dendritic cells infected with selected lentivirus targeting hit genes. 
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Taken together, and focusing on the 13 genes with a correlating IFN-γ 
secretion and OT-I T cell proliferation phenotype, we could observe that the 
knockdown of seven of these genes affected IFN-γ secretion for both OT-I and 
OT-II derived T-cells, while six putative negative regulators seemed to affect 
only OT-I IFN-γ secretion (genes in which we decided to focus from this stage 
on). This is summarized in table 8. 
 
Table 8 - Summary of correlating genes with a differential IFN-γ secretion by OT-I 
and OT-II derived T-cells. 
 
Gene symbol IFN-γ OT-I secretion IFN-γ OT-II secretion 
Vdac3 +  
Pim2 +  
Gucy1b2 +  
Pfkl +  
Nrp2 + + 
Erbb3 + + 
Dnajb8 +  
Dnajc5 + + 
Ptpn7 +  
Pdpk1 - - 
XM_355257 - - 
Hipk2 - - 
Gm711 - - 
+ Putative negative regulators; - putative positive regulators 
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1.3 Selection and validation of gene hits 
 
At this point, we decided to “categorize” the gene hits obtained, according to 
the different aspects of the antigen presentation analyzed and described in the 
previous points. The characterization work conducted is summarized in table 9. 
 
Table 9 – Summary of more detailed characterization conducted in the selected hit 
genes. 
 
Gene symbol∗ B3Z IL-12 TNF-α IL-6 
Prolif. 
OT-I 
IFN-γ 
OT-I 
IFN-γ 
OT-II 
H-2Kb CD86 OVA_DQ 
4.933423E+23 
(5) +    +      
1700011K15Rik 
(5) (Prps1l1)     +      
Acvr1c (3)     +      
Acvr2a (5)  -   -      
Adck1 (4)     +      
Adck2 (5)     +      
Bag1 (5)     -      
C330011J12Rik 
(4) (Pik3c2b)     +      
Calm2 (3) +    +      
Canx (2)     -      
Cdc25a (4)     -      
Cdk3 (2)     +      
Chek1 (4)     +      
Chek2 (4)     +      
Csnk1d (3)     -      
Csnk2a2 (4)     -      
Dapk1 (3)     +      
Ddr2 (3)     +      
Dgki (3)     -      
Dlgh1 (4) +    +      
Dlgh3 (5) +    +      
Dmpk (2)  + + + +    +  
Dnaja2 (4)  -   - - - -   
Dnajb5 (5)     -      
Dnajb6 (3)     -      
                                                
∗ In brackets, shRNA construct number with best phenotype. 
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Dnajb8 (4)     + +     
Dnajc5 (1)     + + +    
Dnajc7 (3)  +   +      
Dnm1l (2)     +      
Doc2b (1)  -   -      
Erbb3 (1) + +   + + +    
Gcs1(1)     +     + 
Gm1079 (4) 
(Sbk2)     +      
Gm1757 (2) -    -      
Gm1890 (2)     +      
Gm234 (3)     +      
Gm711 (1)     - - -    
Gsk3b (5)     +      
Gucy1b2 (3)  +   + + +    
Gucy2f (3)     +      
Hipk2 (3) -    - - -    
Hkdc1 (1)     +      
Insrr (3)     +      
LOC241051 (1)     +      
Map2k5 (4)     +      
Mapk7 (4)  +  + +      
Meis1 (4)     +      
Met (1)     +      
Mertk (1) -    -      
Nek8 (5)     +      
Nlk (5) -    -      
Nrp2 (3)     + + +    
Pdpk1 (3) - -   - - - - -*  
Pfkl (5) +    + +     
Pin1 (4)   +  +      
Pim2 (2) +    + +     
Pim3 (2)     -   -   
Ppp3r1 (5)     +      
Prkab1 (2)     +      
Prkar1b (3)     +      
                                                
* As individually tested compared to control. Data not shown. 
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Prkcsh (5)     +      
Prkdc (5)     +      
Ptpn14 (2)     +      
Ptpn18 (2)     +      
Ptpn7 (2) +  +  + +     
Ptprg (2)     -      
Rad9 (3)     -      
Rock1 (5)     +      
Rps6kl1 (4)     +      
Stk32b (5)     +      
Stub1 (4)     +      
Syk (3)     +      
Taok2 (5)     +      
Tssk3 (4)     +      
UNK, 
XM_126461 (2)     -      
UNK, 
XM_357926 (4) -    -      
UNK, 
XM_355257 (3) -    - - -    
UNK, 
XM_356631 (4)     +      
UNK, 
XM_357598 (4)     +      
UNK, 
XM_358804 (4)     -      
Vdac3 (1)     + +    + 
+ putative negative regulators; - putative positive regulators 
 
As such from the list of genes for detailed validation, we decided to focus in 
groups of genes with a phenotype not only in cross-presentation, but also in 
other aspects of antigen presentation. Hence, we decided to conduct qPCR 
measurements of remaining mRNA transcripts for correlation of observed 
phenotype with gene knockdown level for groups of genes that matched this 
criterion (fig. 39). 
Therefore, nine genes (Acvr2a, Dmpk, Dnaja2, Dnajc7, Doc2b, Erbb3, 
Gucy1b2, Mapk7 and Pdpk1) that produced a phenotype both for cross-
presentation and IL-12 secretion were tested; concomitantly, three genes 
(Dnajb8, Pim2 and Vdac3) that putatively affected cross-presentation in a 
specific manner were also examined. Although Pfkl and Ptpn7 did not show an 
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increased IFN-γ secretion for class II (at the defined confidence level), the 
obtained Z-score for IFN-γ secretion was much higher (data not shown) than 
that observed for Dnajb8, Pim2 and Vdac3, for which it was decided not to 
include these genes for further investigation. In addition, Gcs1 was also 
included in the gene list for further validation for its antigen processing 
phenotype. 
It should also be noted that although five additional genes (Dnajc5, Gm711, 
Hipk2, Nrp2 and XM_355257) produced a correlating and significant 
phenotype, this was true in both the context of class I and II; as the aim of our 
study was the identification of genes with a role in antigen cross-presentation, 
further studies were not pursued at this point. 
The obtained results are summarized in table 10. 
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Figure 39 - mRNA expression as determined by qPCR following infection of BMDCs 
with lentiviruses expressing shRNAs targeting the indicated genes. Constructs producing 
best phenotype are boxed. Data are from one of at least 2 independent experiments. 
 
 
Table 10 – Summary for gene knockdown level correlation with phenotype for hit 
genes (in brackets is indicated shRNA number that provided observed phenotype). 
 
Gene symbol Knockdown correlation 
Acvr2a (5) No correlation 
Dmpk (2) Not sufficiently expressed 
Dnaja2 (4) Correlates 
Dnajb8 (4) Correlates 
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Dnajc7 (3) No correlation 
Doc2b (1) Not sufficiently expressed 
Erbb3 (1) Correlates 
Gcs1 (1) Correlates 
Gucy1b2 (3) No correlation 
Mapk7 (4) No correlation 
Pdpk1 (3) Correlates 
Pim2 (2) Correlates 
Vdac3 (1) No correlation 
  
 
As it can be observed from table 10, six genes showed a good correlation 
between knockdown level and phenotype, i.e., we validated ≅ 45% of the 
phenotipically identified genes, which is well within the expected rate of 
validation (TRC, unpublished). From the six genes, four (Pdpk1, Dnaja2, Gcs1 
and Pim2) had available antibodies; however, only for two of these (Pdpk1 and 
Pim2) we could obtain specific immunoblot results (fig. 40 and 41). In the case 
of Pdpk1 (fig.40), the protein level of expression correlates with the best 
knockdown construct (as already confirmed by qPCR). On the other hand, 
though Pim2 had shown a correlation between phenotype and gene knockdown 
at mRNA level, that was not observed at the protein level (fig. 41).  
 
 
 
Figure 40 - Protein expression measured by Western blot for Pdpk1. Construct 2 has 
failed to clone. 
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Figure 41 - Protein expression measured by Western blot for Pim2. 
 
 
 
In addition, IL-12 was assessed at a transcriptional level 8h after LPS 
stimulation (fig. 42), along with its secretion by ELISA (fig. 43) for Dnaja2, 
Pdpk1 and Erbb3, as the targeting of these genes had shown also to produce a 
phenotype at the signal 3 level. As it can be observed at the considered time 
point, in the case of Dnaja2, for construct #4 (which provides the most 
significant phenotype) there is a down regulation of IL-12 levels, when 
compared to the other target hairpins and control, even if not statistically 
significant.  In the case of Erbb3, construct #1 exhibits lower levels of IL-12 
expression when compared to control, although its secretion is higher as 
measured by ELISA. Relatively to Pdpk1, all targeting constructs lead to low IL-
12 expression levels, although only constructs #3 and #5 lead to low secretion 
(fig. 43). 
 
 
 
 
Figure 42 – IL12p40 mRNA expression as determined by qPCR following infection of 
BMDCs with lentiviruses expressing shRNAs targeting the indicated genes, 8h after LPS 
(1µg/ml) challenge. Constructs producing best phenotype are boxed. ND - not 
detectable; FC – failed to clone. Data are from one of at least 2 independent 
experiments. 
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Figure 43 – IL-12 secretion by dendritic cells infected with lentivirus targeting the 
indicated genes measured 8h after LPS (1µg/ml) challenge. Constructs producing best 
phenotype are boxed. Pdpk1 #II failed to clone. Data is representative from 2 
independent experiments. * - p<0.05 
 
 
 
Taking together the described results, we were able to validate one gene that 
putatively affects cross-presentation in a specific manner: Dnajb8. Dnajb8 is a 
heat-shock protein belonging to the conserved DNAJ/HSP40 family of proteins, 
which regulate molecular chaperone activity by stimulating ATPase activity 
(Ohtsuka and Hata, 2000).  
We also validated Gcs1 (glucosidase 1, also termed as Mogs - mannosyl-
oligosaccharide glucosidase), a protein located in the ER lumen and that has 
been implicated in congenital glycosilation disorders. 
As previously shown, from the nine genes whose targeting produced a 
phenotype in both antigen cross-presentation and IL-12 secretion, only three 
were validated: Dnaja2, Erbb3 and Pdpk1. Similarly to Dnajb8, Dnaja2 also 
belongs to the DNAJ/HSP40 family of proteins. Recently, Dnaja2 was shown to 
work as a co-chaperone of Hsp70s in protein folding and mitochondrial protein 
import in vitro (Tzankov et al., 2008). As reviewed by (Srivastava, 2002), several 
studies have implicated heat-shock proteins (HSPs) in efficient CTL priming, by 
acting as molecular chaperones and in protein folding and stability. Also, as 
(Heath et al., 2004) point out, there are specific receptor-mediated mechanisms 
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for capture and internalization of HSPs by DCs (Arnold-Schild et al., 1999; 
Singh-Jasuja et al., 2000), suggesting that “cross-presentation of HSP-derived 
antigenic determinants is a legitimate mechanism for cross-presentation by 
DCs”. Thus, it is legitimate to expect HSP genes as hits in the studied context. 
Nevertheless, a recent report claims that the reported antigen and cross-
presentation role and in vitro HSP cytokine functions are a result of molecules 
bound to (possible contaminants) or chaperoned by HSPs, but not a result of 
HSPs themselves (Tsan and Gao, 2009). Concerning Erbb3 (v-erb-b2 
erythroblastic leukemia viral oncogene homolog 3), this is a member of the 
epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, 
whose expression has been reported in different types of cancers (Koutras et al., 
2008; Rickman et al., 2009; Yu et al., 2008). Even though in mice only one 
transcript is described, in humans have been reported six isoforms, in which 
one lacks the intermembrane domain and is actually secreted (Chen et al., 
2007). 
Finally, the most consistently validated hit, Pdpk1, showed a phenotype for 
both cross-presentation and class II. In addition, the two validated constructs 
targeting this gene also decreased the secretion of pro-inflammatory cytokines 
(TNF-α and IL-12), MHC-I and CD86 expression, along with antigen processing. 
Pdpk1 (3-phosphoinositide dependent protein kinase-1, also termed as PDK1) is 
a master kinase that acts upstream of several members of the AGC kinases such 
as PKB, PKC, PRK1, RSK, S6K and SGK, being a member of this family itself 
(Mora et al., 2004). Pdpk1 has been implicated in embryonic development 
(Lawlor et al., 2002) and in normal liver (Mora et al., 2005a) and heart (Mora et 
al., 2005b) functions. In addition, studies have shown Pdpk1 to have a role in 
thymocyte development (Hinton et al., 2004) and to be involved in IL-4 
secretion by TH2 cells (Nirula et al., 2006). More recently, (Zaru et al., 2008) 
have addressed the role of Pdpk1 in dendritic cell biology using mice 
expressing 10% of Pdpk1 activity (Pdpk1 total loss is embryonic lethal), pointing 
out effects at the level of cytokine production, phagocytosis and TLR-induced 
macropinocytosis, although with different outcomes when considering distinct 
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DC populations, which were not conclusively addressed in this report and await 
further confirmation. 
 
 
Concomitantly, we investigated the described protein interacting networks 
for all of the 81 genes selected for detailed characterization (excluding those 
that were not validated), in order to assess the possible occurrence of 
connections among these. As such, one gene-centered search was observed to 
be in this context: Stub1.  
 Stub1 interactions with two targeted genes have been described (Bag1 and 
Dapk1) as depicted in fig. 44 (Tateishi et al., 2004; Wojcik, 2002; Zhang et al., 
2007). In particular, Stub1 has been shown to mediate ubiquination of Bag1 
(Alberti et al., 2002) and its interaction with Dapk1 increases ubiquination of 
Dapk1 itself (Zhang et al., 2007). 
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Figure 44 - Described interactions for Stub1 protein. Targeted genes by our screen have 
been highlighted: red – putative negative regulators; green - putative positive regulators. From 
Ingenuity Pathways Analysis (Ingenuity Systems).  
 
 
 
Focusing exclusively in kinases and phosphatases (from the 81 member 
group, and excluding those that were not validated), we decided to test 
commercially available drugs targeting these genes. Fig. 45 depicts examples of 
possible positive (Dgki) and negative (Acvr1c) regulators of antigen presentation, 
which produced a phenotype that correlates well with our observations when 
these genes were silenced using shRNA. 
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Figure 45 – Examples of antigen cross-presentation assays in the presence of inhibitory drugs 
targeting kinases and phosphatases hit genes. Targeted genes, inhibitory drugs and tested 
conditions are depicted. * - p<0.05 
 
 
 
 
2. Vesicle traffic screen 
 
 
Taking advantage of the continuous expansion and release of the mouse 
lentiviral collection developed by the TRC, we decided to compile a second 
subset of genes to test in the context of cross-presentation, which have been 
shown to be involved in vesicle traffic within the cell. This collection comprises 
Snares, Rabs, Caveolins, Syntaxins, among others (the complete gene list is 
included in the supplementary data, table S2). As previously mentioned, the 
underlying intracellular processes of cross-presentation remain largely 
unknown, despite the fact that several possible mechanisms have been 
proposed (reviewed in the first chapter of this work). Yet, as cross-presentation is 
a constant membrane transport process, the analysis in this context of the most 
comprehensive list of genes available involved in the later, arose as of crucial 
importance. Indeed, very recently, (Zou et al., 2009) have identified Rab3b/3c 
as being involved in cross-presentation by a dendritic cell line (DC2.4), by 
screening 57 Rab GTPases using siRNA targeting. 
The experimental setup followed is similar to that used in the 
kinase/phosphatase screen, with minor changes. Namely, for simplicity 
purposes and having established that soluble OVA elicit an effective T-cell 
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response with this experimental set-up, this was the antigen source of option. 
Also, as this experimental layout was entirely conducted at the Lisbon lab (the 
kinases and phosphatases screen was initiated in Boston, USA), due to some 
radioactivity usage constraints, we devised the CFSE application as a T-cell 
proliferation measurement in a high-throughput scale. The experimental design 
and the described modifications are schematically represented in fig. 46. 
  
 
Figure 46 – Schematic representation of experimental protocol followed in the 
vesicle traffic collection screen. 
 
 
This screen summed-up to approximately 155 genes, producing in the order 
of 800 individual records.  
Similarly to the previously described screen, the number of viable cells in 
each individual well was calculated (all records presenting less than 20000 
viable cells were excluded from further analysis), along with the calculation of 
the T-cell proliferation for each individual hairpin tested into a normalized 
value, the Z-score (as formerly defined). However, the T-cell proliferation was 
measured by introducing a new concept that better reflected the experimental 
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option taken for this screen: the division index (Angulo and Fulcher, 1998; 
Saveanu et al., 2009). The division index is defined as the ratio between the 
number of precursor T-cells and the total number of mitosis that these have 
experienced: 
 
Division index = number  of  mitosisnumber  of  precursors  
 
As such, for each individual tested sample, the different dividing populations 
were defined (two different possible representations are shown in fig. 47), along 
with the respective calculations of the number of precursor cells and 
experienced mitosis as represented bellow:  
 
Number  of  precursors = non dividing cells20  + 
1 division cells
21  + 
2 division cells
22  + ... + 
n division cells
2n
 
 
 
 
Number  mitosis (cells with x divisions) = number  cells with x divisions2  + 
number  cells with x divisions
22  + ... + 
number  cells with x divisions
2x  
 
 
 
 
Figure 47 – Visualization of T-cell proliferation in FACS plots. Left: dots plot 
representation; right: histogram depiction. The different proliferating populations are 
identified in both. 
 
 
After sorting all individual records and analyzing their graphical 
representation (fig. 48), it was possible to convey a criterion to select candidate 
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genes for further validation. This implied that at least two constructs had a Z-
score higher than 1.0 or lower than -0.7 (fig. 48).  
 
 
 
Figure 48 - The criteria used to select candidate genes for following validation 
experiments, implied that two or more constructs presented a deviation of the mean 
proliferation for the plate where it was located (Z-score), higher than 1.0 or lower than -
0.7 as depicted in the graph after sorting each individual record. 
 
 
 
In addition, similarly to the kinase/phosphatase screening, the level of 
secreted IFN-γ was also quantified (fig. 49).  
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Figure 49 – OT-I T-cell IFN-γ secretion by dendritic cells infected with selected 
lentivirus, after soluble OVA (0.1µg/ml) challenge. Results are represented as a Z-score, 
relating to the deviation of each individual hairpin to the mean of the plate where 
located. 
 
 
From the data analysis, it was possible to identify 7 genes (three putative 
positive and four putative negative regulators) among the top hits – Rabl2a, 
Sec23a, Rab19, Rab9, Rab10, Rabif and Rab17 - that presented a differential 
IFN-γ production.   
 
 
From this initial screening step, 43 genes (≅ 28% of the initial screened 
genes, summarized in table 11) were selected for validation in secondary assays 
according to the above-described criteria. This secondary analysis was 
developed in a similar experimental set-up, but in a MHC class II context (fig. 
50 and table 11). From the 43 tested genes, 24-showed similar phenotype in the 
context of class II to the one observed in the cross-presentation assay (and were 
not subjected to further studies at this point) and seven produced inconclusive 
results. Twelve genes that showed a tendency for a specific cross-presentation 
phenotype were chosen for a tertiary phase of validation.  
In addition, fig. 51 shows a schematic representation of Snare interactions in 
vesicular transport within the cell; the targeted genes in the secondary screen 
are depicted with their according phenotype. 
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Table 11 – List of selected hit genes. 
 
Gene Symbol Prolif. OT-I IFN-γ OT-I IFN-γ OT-II 
β2m -   
Bet1 -   
Bet1L -  - 
Copg +  + 
Crot +  + (?) 
Degs1 +   
Dnm1 -   
Rab10 + + + 
Rab17 + +  
Rab19 - -  
Rab2 -   
Rab22a -  - 
Rab2b -  - 
Rab38 -  - 
Rab3gap1 +  + 
Rab40b +   
Rab5c -  - 
Rab6b -  - 
Rab7l1 -  - (?) 
Rab9 + + + (?) 
Rab9b -  - 
Rabep1 -  - (?) 
Rabepk -  - (?) 
Rabgap1l +  + 
Rabif + + + 
Rabl2a - - - 
Sec23a - - - 
Sec24a +  + 
Sec24d +   
Snap25 +  + 
Snap29 -  - 
Snap91 +  + 
Stx17 -  - 
Stx18 -   
Stx1b1 +  + (?) 
Stx1b2 -  - 
Stx3 -  - 
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Stx4a +  + (?) 
Stx6 +  + 
Stx8 -  - 
Sybl1 (Vamp7) +  + 
Vamp4 +   
Vti1a -   
+ negative regulators; - positive regulators 
 
 
 
 
 
 
Figure 50 – OT-II T-cell IFN-γ secretion by dendritic cells infected with selected 
lentivirus, after soluble OVA (0.1µg/ml) challenge. Results are represented as a Z-score, 
relating to the deviation of each individual hairpin to the mean of the plate where 
located. 
 
 
